##### Table of Contents

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549



---



Form 10-Q



---



QUARTERLY REPORT UNDER SECTION 13 OR
15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934



For the Quarterly Period Ended June 30, 2005



Commission File No. 000-19495



---



Embrex, Inc.

(Exact name of registrant as specified in its charter)



---



|                                                               |  |                                  
|-------------------------------------------------------------- |  | ---------------------------------
|North Carolina                                                 |  | 56-1469825                       
|(State or other jurisdiction of incorporation or organization) |  | (IRS Employer Identification No.)



|                                         |  |           
|---------------------------------------- |  | ----------
|1040 Swabia Court, Durham, NC            |  | 27703     
|(Address of principal executive offices) |  | (Zip Code)



Registrants
telephone no. including area code: (919) 941-5185



---



Check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No ̈



Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of
1934).    Yes  x    No ̈



The number of shares of Common Stock, $0.01 par value, outstanding as of July 20, 2005 was
8,060,316.



---



---

##### Table of Contents

EMBREX, INC.



INDEX



|        |  |                                                                                       |  |         
|------- |  | ------------------------------------------------------------------------------------- |  | --------
|        |  |                                                                                       |  | Page    
|Part I  |  |                                                                                       |  |         
|        |  | Financial Information:                                                                |  |         
|        |  |                                                                                      
|        |  | Item 1: Consolidated Financial Statements                                             |  |         
|        |  |                                                                                      
|        |  | Consolidated Balance Sheets                                                           |  | 2 of 38 
|        |  |                                                                                      
|        |  | Consolidated Statements of Operations                                                 |  | 4 of 38 
|        |  |                                                                                      
|        |  | Consolidated Statements of Cash Flows                                                 |  | 5 of 38 
|        |  |                                                                                      
|        |  | Notes to Consolidated Financial Statements                                            |  | 6 of 38 
|        |  |                                                                                      
|        |  | Item 2:                                                                               |  |         
|        |  |                                                                                      
|        |  | Managements Discussion and Analysis of Financial Condition and Results of Operations |  | 14 of 38
|        |  |                                                                                      
|        |  | Item 3:                                                                               |  |         
|        |  |                                                                                      
|        |  | Quantitative and Qualitative Disclosures About Market Risk                            |  | 33 of 38
|        |  |                                                                                      
|        |  | Item 4:                                                                               |  |         
|        |  |                                                                                      
|        |  | Controls and Procedures                                                               |  | 34 of 38
|        |  |                                                                                      
|Part II |  |                                                                                       |  |         
|        |  |                                                                                      
|        |  | Other Information:                                                                    |  |         
|        |  |                                                                                      
|        |  | Item 1: Legal Proceedings                                                             |  | 35 of 38
|        |  |                                                                                      
|        |  | Item 2: Unregistered Sales of Equity Securities and Use of Proceeds                   |  | 35 of 38
|        |  |                                                                                      
|        |  | Item 3: Defaults Upon Senior Securities                                               |  | 35 of 38
|        |  |                                                                                      
|        |  | Item 4: Submission of Matters to a Vote of Security Holders                           |  | 36 of 38
|        |  |                                                                                      
|        |  | Item 5: Other Information                                                             |  | 36 of 38
|        |  |                                                                                      
|        |  | Item 6: Exhibits                                                                      |  | 36 of 38
|        |  |                                                                                      
|        |  | Signatures                                                                            |  | 37 of 38
|        |  |                                                                                      
|        |  | Exhibit Index                                                                         |  | 38 of 38



- 2 -



---

##### Table of Contents

PART I - FINANCIAL INFORMATION



Item 1. Consolidated Financial Statements



Embrex, Inc.



Consolidated Balance Sheets

(Dollars in thousands)

(*Unaudited)



|                                                                                                                                                                                                        |  |               |         |   |                  |   |         |  
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ------------- | ------- | - | ---------------- | - | ------- | -
|                                                                                                                                                                                                        |  | June 30,2005* |         |   | December 31,2004 |  
|ASSETS                                                                                                                                                                                                  |  |               |         |   |                  |   |         |  
|Current Assets                                                                                                                                                                                          |  |               |         |   |                  |   |         |  
|Cash and cash equivalents                                                                                                                                                                               |  | $             | 1,890   |   |                  | $ | 4,469   |  
|Restricted cash                                                                                                                                                                                         |  |               | 115     |   |                  |   | 115     |  
|Accounts receivable  trade, net                                                                                                                                                                        |  |               | 7,120   |   |                  |   | 7,816   |  
|Inventories:                                                                                                                                                                                            |  |               |         |   |                  |   |         |  
|Materials and supplies                                                                                                                                                                                  |  |               | 2,451   |   |                  |   | 2,107   |  
|Product                                                                                                                                                                                                 |  |               | 1,377   |   |                  |   | 1,448   |  
|Current deferred tax asset                                                                                                                                                                              |  |               | 905     |   |                  |   | 706     |  
|Other current assets                                                                                                                                                                                    |  |               | 1,804   |   |                  |   | 2,846   |  
|                                                                                                                                                                                                        |  |               |         |   |                  |   |         |  
|Total Current Assets                                                                                                                                                                                    |  |               | 15,662  |   |                  |   | 19,507  |  
|                                                                                                                                                                                                        |  |              
|Land                                                                                                                                                                                                    |  |               | 147     |   |                  |   | 147     |  
|                                                                                                                                                                                                        |  |              
|Devices under construction                                                                                                                                                                              |  |               | 3,788   |   |                  |   | 3,055   |  
|                                                                                                                                                                                                        |  |              
|Devices                                                                                                                                                                                                 |  |               | 50,993  |   |                  |   | 47,379  |  
|Less accumulated depreciation                                                                                                                                                                           |  |               | (32,755 | ) |                  |   | (31,864 | )
|                                                                                                                                                                                                        |  |               |         |   |                  |   |         |  
|                                                                                                                                                                                                        |  |               | 18,238  |   |                  |   | 15,515  |  
|                                                                                                                                                                                                        |  |              
|Plant and Equipment                                                                                                                                                                                     |  |               | 30,436  |   |                  |   | 28,953  |  
|Less accumulated depreciation and amortization                                                                                                                                                          |  |               | (10,445 | ) |                  |   | (9,704  | )
|                                                                                                                                                                                                        |  |               |         |   |                  |   |         |  
|                                                                                                                                                                                                        |  |               | 19,991  |   |                  |   | 19,249  |  
|Other Assets                                                                                                                                                                                            |  |               |         |   |                  |   |         |  
|Intangible assets (net of accumulated amortization of $609 in 2005 and $538 in 2004)                                                                                                                    |  |               | 4,816   |   |                  |   | 4,025   |  
|Long-term deferred tax asset                                                                                                                                                                            |  |               | 797     |   |                  |   | 949     |  
|Other long-term assets                                                                                                                                                                                  |  |               | 174     |   |                  |   | 133     |  
|                                                                                                                                                                                                        |  |               |         |   |                  |   |         |  
|Total Other Assets                                                                                                                                                                                      |  |               | 5,787   |   |                  |   | 5,107   |  
|                                                                                                                                                                                                        |  |               |         |   |                  |   |         |  
|Total Assets                                                                                                                                                                                            |  | $             | 63,613  |   |                  | $ | 62,580  |  
|                                                                                                                                                                                                        |  |               |         |   |                  |   |         |  
|LIABILITIES AND SHAREHOLDERS EQUITY                                                                                                                                                                    |  |               |         |   |                  |   |         |  
|Current Liabilities                                                                                                                                                                                     |  |               |         |   |                  |   |         |  
|                                                                                                                                                                                                        |  |              
|Accounts payable                                                                                                                                                                                        |  | $             | 455     |   |                  | $ | 887     |  
|Accrued expenses                                                                                                                                                                                        |  |               | 4,096   |   |                  |   | 5,351   |  
|Deferred revenue                                                                                                                                                                                        |  |               | 310     |   |                  |   | 145     |  
|Product warranty accrual                                                                                                                                                                                |  |               | 150     |   |                  |   | 136     |  
|Current portion of long-term debt                                                                                                                                                                       |  |               | 508     |   |                  |   | 514     |  
|Current portion of capital lease obligations                                                                                                                                                            |  |               | 11      |   |                  |   | 7       |  
|                                                                                                                                                                                                        |  |               |         |   |                  |   |         |  
|Total Current Liabilities                                                                                                                                                                               |  |               | 5,530   |   |                  |   | 7,040   |  
|                                                                                                                                                                                                        |  |              
|Long-term debt, less current portion                                                                                                                                                                    |  |               | 8,296   |   |                  |   | 8,516   |  
|Capital Lease Obligations, less current portion                                                                                                                                                         |  |               | 14      |   |                  |   | 2       |  
|                                                                                                                                                                                                        |  |              
|Shareholders Equity                                                                                                                                                                                    |  |               |         |   |                  |   |         |  
|Common Stock, $0.01 par value per share:                                                                                                                                                                |  |               |         |   |                  |   |         |  
|Authorized - 30,000,000 shares; Issued and outstanding - 7,989,317 net of 1,674,666 treasury shares and 7,921,605 net of 1,674,666 treasury
shares at June 30, 2005 and December 31, 2004, respectively |  |               | 96      |   |                  |   | 95      |  
|Additional paid-in capital                                                                                                                                                                              |  |               | 66,630  |   |                  |   | 64,938  |  
|Accumulated other comprehensive income                                                                                                                                                                  |  |               | 421     |   |                  |   | 196     |  
|Deferred compensation                                                                                                                                                                                   |  |               | (1,747  | ) |                  |   | (725    | )
|Retained earnings                                                                                                                                                                                       |  |               | 4,220   |   |                  |   | 2,365   |  
|Treasury stock                                                                                                                                                                                          |  |               | (19,847 | ) |                  |   | (19,847 | )
|                                                                                                                                                                                                        |  |               |         |   |                  |   |         |  
|Total Shareholders Equity                                                                                                                                                                              |  |               | 49,773  |   |                  |   | 47,022  |  
|                                                                                                                                                                                                        |  |               |         |   |                  |   |         |  
|Total Liabilities and Shareholders Equity                                                                                                                                                              |  | $             | 63,613  |   |                  | $ | 62,580  |  
|                                                                                                                                                                                                        |  |               |         |   |                  |   |         |  



See
accompanying notes.



- 3 -



---

##### Table of Contents

Embrex, Inc.



Consolidated Statements of
Operations

(Unaudited)

(In thousands, except
per share amounts)



|                                                |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|----------------------------------------------- |  | ------------------------- | ------ | - | ----------------------- | - | ------ | ---- |  | - | ------ | - |  | - | ------ | -
|                                                |  | Three Months EndedJune 30 |        |   | Six Months EndedJune 30 |  
|                                                |  | 2005                      |        |   | 2004                    |   |        | 2005 |  |   | 2004   |  
|Revenues                                        |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|Device revenues                                 |  | $                         | 12,172 |   |                         | $ | 11,052 |      |  | $ | 24,094 |   |  | $ | 22,553 |  
|Product sales                                   |  |                           | 724    |   |                         |   | 560    |      |  |   | 1,423  |   |  |   | 852    |  
|Other revenue                                   |  |                           | 122    |   |                         |   | 115    |      |  |   | 264    |   |  |   | 278    |  
|                                                |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|Total Revenues                                  |  |                           | 13,018 |   |                         |   | 11,727 |      |  |   | 25,781 |   |  |   | 23,683 |  
|                                                |  |                           |        |  
|Cost of Device Revenues and Product Sales       |  |                           | 5,487  |   |                         |   | 4,774  |      |  |   | 10,980 |   |  |   | 9,610  |  
|                                                |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|Gross Profit                                    |  |                           | 7,531  |   |                         |   | 6,953  |      |  |   | 14,801 |   |  |   | 14,073 |  
|                                                |  |                           |        |  
|Operating Expenses                              |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|General and administrative                      |  |                           | 2,694  |   |                         |   | 2,302  |      |  |   | 5,268  |   |  |   | 4,854  |  
|Sales and marketing                             |  |                           | 1,216  |   |                         |   | 689    |      |  |   | 2,195  |   |  |   | 1,334  |  
|Research and development                        |  |                           | 2,249  |   |                         |   | 2,555  |      |  |   | 5,000  |   |  |   | 4,754  |  
|                                                |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|Total Operating Expenses                        |  |                           | 6,159  |   |                         |   | 5,546  |      |  |   | 12,463 |   |  |   | 10,942 |  
|                                                |  |                           |        |  
|Operating Income                                |  |                           | 1,372  |   |                         |   | 1,407  |      |  |   | 2,338  |   |  |   | 3,131  |  
|                                                |  |                           |        |  
|Other Income (Expense)                          |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|Interest income                                 |  |                           | 42     |   |                         |   | 20     |      |  |   | 64     |   |  |   | 41     |  
|Interest expense                                |  |                           | (19    | ) |                         |   | (4     | )    |  |   | (25    | ) |  |   | (16    | )
|Foreign currency gain                           |  |                           | 50     |   |                         |   | 81     |      |  |   | 177    |   |  |   | 104    |  
|                                                |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|Total Other Income                              |  |                           | 73     |   |                         |   | 97     |      |  |   | 216    |   |  |   | 129    |  
|                                                |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|Income Before Income Tax Expense                |  |                           | 1,445  |   |                         |   | 1,504  |      |  |   | 2,554  |   |  |   | 3,260  |  
|Income Tax Expense                              |  |                           | 199    |   |                         |   | 698    |      |  |   | 698    |   |  |   | 1,345  |  
|                                                |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|Net Income                                      |  | $                         | 1,246  |   |                         | $ | 806    |      |  | $ | 1,856  |   |  | $ | 1,915  |  
|                                                |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|Net Income per share of Common Stock:           |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|Basic                                           |  | $                         | 0.16   |   |                         | $ | 0.10   |      |  | $ | 0.23   |   |  | $ | 0.24   |  
|Diluted                                         |  | $                         | 0.15   |   |                         | $ | 0.10   |      |  | $ | 0.22   |   |  | $ | 0.23   |  
|                                                |  |                           |        |  
|Number of Shares Used in Per Share Calculation: |  |                           |        |   |                         |   |        |      |  |   |        |   |  |   |        |  
|Basic                                           |  |                           | 7,964  |   |                         |   | 7,960  |      |  |   | 7,950  |   |  |   | 7,997  |  
|Diluted                                         |  |                           | 8,278  |   |                         |   | 8,268  |      |  |   | 8,275  |   |  |   | 8,308  |  



See accompanying notes.



- 4 -



---

##### Table of Contents

Embrex, Inc.



Consolidated Statements of Cash
Flows

(Unaudited)

(In thousands)



|                                                                                                  |  |                         |        |   |      |   |        |  
|------------------------------------------------------------------------------------------------- |  | ----------------------- | ------ | - | ---- | - | ------ | -
|                                                                                                  |  | Six Months EndedJune 30 |       
|                                                                                                  |  | 2005                    |        |   | 2004 |  
|Operating Activities                                                                              |  |                         |        |   |      |   |        |  
|                                                                                                  |  |                        
|Net income                                                                                        |  | $                       | 1,856  |   |      | $ | 1,915  |  
|Adjustments to reconcile net income to net cash provided by operating activities:                 |  |                         |        |   |      |   |        |  
|Depreciation and amortization                                                                     |  |                         | 3,117  |   |      |   | 2,821  |  
|Loss on sale of fixed assets                                                                      |  |                         | 15     |   |      |   | 3      |  
|Change in restricted cash                                                                         |  |                         | (1     | ) |      |   | 91     |  
|Change in deferred tax asset                                                                      |  |                         | (48    | ) |      |   | 350    |  
|Restricted stock amortization                                                                     |  |                         | 271    |   |      |   | 121    |  
|Changes in operating assets and liabilities:                                                      |  |                         |        |   |      |   |        |  
|Accounts receivable, inventories and other current assets                                         |  |                         | 1,484  |   |      |   | 733    |  
|Accounts payable, accrued expenses, deferred revenue and warranty accrual                         |  |                         | (1,508 | ) |      |   | (1,227 | )
|                                                                                                  |  |                         |        |   |      |   |        |  
|Net Cash Provided By Operating Activities                                                         |  |                         | 5,186  |   |      |   | 4,807  |  
|                                                                                                  |  |                        
|Investing Activities                                                                              |  |                         |        |   |      |   |        |  
|Purchases of devices, equipment, furniture and fixtures                                           |  |                         | (7,266 | ) |      |   | (5,053 | )
|Cash proceeds from sale of devices, equipment, furniture and fixtures                             |  |                         | 10     |   |      |   | 29     |  
|Investment in patents and other non-current assets                                                |  |                         | (905   | ) |      |   | (499   | )
|                                                                                                  |  |                         |        |   |      |   |        |  
|Net Cash Used In Investing Activities                                                             |  |                         | (8,161 | ) |      |   | (5,523 | )
|                                                                                                  |  |                        
|Financing Activities                                                                              |  |                         |        |   |      |   |        |  
|Issuance of common stock                                                                          |  |                         | 381    |   |      |   | 465    |  
|Drawdown/(Repayment) of short-term debt                                                           |  |                         | -0-    |   |      |   | (894   | )
|Drawdown/(Repayment) of long-term debt, capital lease obligations and other long-term liabilities |  |                         | (209   | ) |      |   | 2,397  |  
|Repurchase of common stock                                                                        |  |                         | -0-    |   |      |   | (2,949 | )
|                                                                                                  |  |                         |        |   |      |   |        |  
|Net Cash Provided By (Used In) Financing Activities                                               |  |                         | 172    |   |      |   | (981   | )
|                                                                                                  |  |                         |        |   |      |   |        |  
|Decrease in cash and cash equivalents                                                             |  |                         | (2,803 | ) |      |   | (1,697 | )
|Currency translation adjustments                                                                  |  |                         | 224    |   |      |   | (227   | )
|Cash and cash equivalents at beginning of period                                                  |  |                         | 4,469  |   |      |   | 9,629  |  
|                                                                                                  |  |                         |        |   |      |   |        |  
|Cash And Cash Equivalents At End Of Period                                                        |  | $                       | 1,890  |   |      | $ | 7,705  |  
|                                                                                                  |  |                         |        |   |      |   |        |  



See accompanying notes.



- 5 -



---

##### Table of Contents

FORM 10-Q

June 30, 2005



NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)



Note 1 - Basis of Presentation



The accompanying unaudited consolidated financial statements include the accounts of Embrex, Inc. and its wholly owned subsidiaries, Embrex Europe Limited, Embrex France s.a.s., Embrex Iberica, Embrex BioTech Trade
(Shanghai) Co., Ltd., Inovoject do Brasil Ltda., Embrex Poultry Health, LLC, Embrex de Mexico S. de R.L. de C.V. and Vaccination Services S. de R.L. de C.V. (Embrex or the Company) and have been prepared in accordance with
accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the
information and notes required by accounting principles generally accepted in the United States. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial
condition and results of operations have been included. Operating results for the three-month and six-month periods ended June 30, 2005 are not necessarily indicative of the results that may be attained for the entire year. For further information,
refer to the consolidated financial statements and notes thereto included in the Companys Form 10-K for the year ended December 31, 2004.



Note 2  Critical Accounting Policies



The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates including but not limited to those related to:



| |  |  | Allowance for uncollectible accounts
| | - |  | ------------------------------------



| |  |  | Warranty accruals
| | - |  | -----------------



| |  |  | Inventory obsolescence
| | - |  | ----------------------



| |  |  | Deferred tax assets
| | - |  | -------------------



| |  |  | Employee fringe benefit plan accrual
| | - |  | ------------------------------------



The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which
form the basis of making judgments about carrying values of assets and liabilities that are not readily discernible from other sources. Actual results may differ from these estimates under different assumptions or conditions.



The Company believes the following critical accounting policies are material to the
preparation of its consolidated financial statements.



Revenue
Recognition



Revenues for devices subject to lease agreements are
recognized based on eggs processed during the period in accordance with lease terms. Device and product sales are recognized upon delivery, which is when title passes to the customer. Contract research revenue is recognized as services are performed
or as milestones are met over the term of the contract. Grant revenue is recognized as expenses related to the specific grants are incurred. Revenue received, but not yet earned, is classified as deferred revenue. The revenue section of the
consolidated statements of operations divides revenues into three sections: device revenues, which include device lease fees and device sales; product sales, which



- 6 -



---

##### Table of Contents

include sales of Bursaplex®; and other revenues, which includes income derived from contract research and
development, grant sources and other minor products.



Allowance for
Uncollectible Accounts



To date, the Company has not experienced any
material trade accounts receivable collection issues. However, based on a review of cumulative balances, industry experience and the current economic environment, the Company currently reserves from approximately 2% to 4% of trade accounts
receivable, depending on the credit terms in various markets, as an allowance for uncollectible accounts. In addition, adjustments due to the financial stability of individual customers will affect the overall percentage reserved. Once the Company
determines an account is uncollectible, it writes off the receivable balance against the reserve. Accounts are written-off based on individual circumstances and only after all efforts of collection have been exhausted. The consolidated balance
reserved for uncollectible accounts as of June 30, 2005 was $0.3 million, which represents 5% of the trade accounts receivable balance at June 30, 2005. The reserve amount has decreased $0.1 million since December 31, 2004. The reserve percentage of
5% currently exceeds the percentage range listed above due primarily to trade accounts receivable in non-U.S. markets.



Warranty Accruals



To date, the Company has not experienced any material device or product warranty issues in excess of amounts reserved. Based on the sale and lease of devices and sale of products, the Company has established a reserve
for future claims. The reserve is based on the estimated damages that a customer would experience if an Inovoject® system or batch of Bursaplex® or Newplex should fail to perform to product specifications. The consolidated balance
reserved for warranties as of June 30, 2005 was $0.1 million.



Inventory
Obsolescence



To date, the Company has not experienced any material
inventory obsolescence. However, based on a percentage of the current product and device parts inventory levels, the Company has established a reserve against future device parts obsolescence due to technological improvements and limited shelf life
of product inventories. The percentage used to calculate the reserve is based on a historical percentage rate adjusted for anticipated technological advances on devices and shelf life of existing vaccine product inventories. The consolidated balance
reserved for product and parts obsolescence as of June 30, 2005 was $0.3 million.



Deferred Tax Assets



The Company records deferred tax assets
based upon amounts that are more likely than not to be realized. Based on the Companys recent profitability and belief that 2005 will result in an overall profit, the Company has recorded net current and long-term deferred tax assets of $1.7
million. The Companys net deferred tax assets include a valuation allowance for two items that the Company may not be able to realize in future periods. The two items are research and development tax credits and deferred tax assets in a
foreign subsidiary. This determination is based, in part, on historical operating performance as well as the likelihood of future income in the near term at certain foreign subsidiaries. The valuation allowance will be reduced when the Company
believes that the likelihood of realizing the deferred tax asset is more likely than not. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, an
adjustment to the deferred tax assets would increase income in the period such determination was made. However, in the event the Company was to determine that it would not be able to realize its net recorded deferred tax asset in the future, an
adjustment to the deferred tax asset would decrease income in the period such determination was made.



- 7 -



---

##### Table of Contents

Employee Fringe Benefit Plan Accrual



The Company has established a reserve related to Embrexs employee fringe benefit plan. The most significant component of the accrual
is the amount reserved for the employee self-insured health plan. The amount of the reserve is based on managements estimate of future employee health claims. The reserve covers expected short-term claims and is based on historical data
adjusted for major events. The net balance reserved for the employee self-insured health plan as of June 30, 2005 was $0.2 million.



IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS



In December 2004, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 123 (revised
2004), Share-Based Payment (SFAS 123(R)). SFAS 123(R), a revision of SFAS 123, Accounting for Stock-Based Compensation, supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees, and
amends SFAS No. 95, Statement of Cash Flows. SFAS 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. SFAS 123(R) is
effective for the beginning of the first interim or annual period beginning after December 31, 2005. Therefore, the Company plans to adopt SFAS 123(R) on January 1, 2006. The Company is currently evaluating the two fair value pricing methods
permitted by SFAS 123(R) and has not selected a final fair value pricing model nor determined the impact such model will have on the Companys financial statements.



In November 2004, the FASB issued FASB Interpretation No. 151, Inventory Costs - an amendment of ARB No. 43, Chapter 4
(FASB 151). This Statement amends the guidance in ARB No. 43, Chapter 4, Inventory Pricing, to clarify the accounting for abnormal amounts of idle facility expense, freight, handling costs, and wasted material (spoilage).
This Statement requires that those items be recognized as current-period charges regardless of whether they meet the criterion of so abnormal. In addition, this Statement requires that allocation of fixed production overheads to the
costs of conversion be based on the normal capacity of the production facilities. The adoption of FASB 151 is not expected to have a material impact on the financial statements of Embrex, Inc.



STOCK-BASED COMPENSATION



The Companys stock plans (the Plans) are designed to provide incentives to eligible employees, officers, and directors in
the form of awards of stock, restricted stock units, stock appreciation rights,



- 8 -



---

##### Table of Contents

incentive stock options, and non-qualified stock options. The Company accounts for the Plans under the recognition and
measurement principles of Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (APB 25) and related interpretations. No stock-based employee compensation cost is reflected in net income with
respect to options granted under current plans, as all options granted under the Plans had an exercise price equal to the market value of the underlying common stock on the date of grant. However, net income does reflect the cost of restricted stock
awards granted. The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of FASB Statement No. 123, Accounting for Stock-Based Compensation
(SFAS 123), as amended by FASB Statement No. 148, Accounting for Stock-Based Compensation  Transition and Disclosure (SFAS 148) (in thousands, except per share amounts):



|                                                                                                                                    |  |                                      |       |   |                                    |   |      |      |  |   |       |   |  |   |       |  
|----------------------------------------------------------------------------------------------------------------------------------- |  | ------------------------------------ | ----- | - | ---------------------------------- | - | ---- | ---- |  | - | ----- | - |  | - | ----- | -
|                                                                                                                                    |  | Three Months EndedJune 30(unaudited) |       |   | Six Months EndedJune 30(unaudited) |  
|                                                                                                                                    |  | 2005                                 |       |   | 2004                               |   |      | 2005 |  |   | 2004  |  
|Net income, as reported                                                                                                             |  | $                                    | 1,246 |   |                                    | $ | 806  |      |  | $ | 1,856 |   |  | $ | 1,915 |  
|Add:       Non-cash stock-based compensation included in net income, net of related tax
effects                                     |  |                                      | 151   |   |                                    |   | 37   |      |  |   | 197   |   |  |   | 71    |  
|Deduct:  Total stock-based compensation expense determined under fair value based method for all awards, net of related tax
effects |  |                                      | (341  | ) |                                    |   | (201 | )    |  |   | (527  | ) |  |   | (551  | )
|                                                                                                                                    |  |                                      |       |   |                                    |   |      |      |  |   |       |   |  |   |       |  
|Pro forma net income                                                                                                                |  | $                                    | 1,056 |   |                                    | $ | 642  |      |  | $ | 1,526 |   |  | $ | 1,435 |  
|                                                                                                                                    |  |                                      |       |   |                                    |   |      |      |  |   |       |   |  |   |       |  
|Earnings per share:                                                                                                                 |  |                                      |       |   |                                    |   |      |      |  |   |       |   |  |   |       |  
|Basicas reported                                                                                                                   |  | $                                    | 0.16  |   |                                    | $ | 0.10 |      |  | $ | 0.23  |   |  | $ | 0.24  |  
|Basicpro forma                                                                                                                     |  | $                                    | 0.13  |   |                                    | $ | 0.08 |      |  | $ | 0.19  |   |  | $ | 0.18  |  
|                                                                                                                                    |  |                                      |       |  
|Dilutedas reported                                                                                                                 |  | $                                    | 0.15  |   |                                    | $ | 0.10 |      |  | $ | 0.22  |   |  | $ | 0.23  |  
|Dilutedpro forma                                                                                                                   |  | $                                    | 0.13  |   |                                    | $ | 0.08 |      |  | $ | 0.18  |   |  | $ | 0.17  |  



The table regarding stock-based
compensation expense and pro-forma net income presented under Note 2 to the Companys interim financial statements included in the Companys Quarterly Report on Form 10-Q for first quarter 2005 that was filed with the Securities and
Exchange Commission on May 3, 2005, inadvertently contained incorrect information. The correct information is reflected in the following table:



|                                                                                                                                    |  |                                       |      |   |      |   |       |  
|----------------------------------------------------------------------------------------------------------------------------------- |  | ------------------------------------- | ---- | - | ---- | - | ----- | -
|                                                                                                                                    |  | Three Months EndedMarch 31(unaudited) |     
|                                                                                                                                    |  | 2005                                  |      |   | 2004 |  
|Net income, as reported                                                                                                             |  | $                                     | 610  |   |      | $ | 1,109 |  
|Add:       Non-cash stock-based compensation included in net income, net of related tax
effects                                     |  |                                       | 46   |   |      |   | 34    |  
|Deduct:  Total stock-based compensation expense determined under fair value based method for all awards, net of related tax
effects |  |                                       | (186 | ) |      |   | (350  | )
|                                                                                                                                    |  |                                       |      |   |      |   |       |  
|Pro forma net income                                                                                                                |  | $                                     | 470  |   |      | $ | 793   |  
|                                                                                                                                    |  |                                       |      |   |      |   |       |  
|Earnings per share:                                                                                                                 |  |                                       |      |   |      |   |       |  
|Basicas reported                                                                                                                   |  | $                                     | 0.08 |   |      | $ | 0.14  |  
|Basicpro forma                                                                                                                     |  | $                                     | 0.06 |   |      | $ | 0.10  |  
|                                                                                                                                    |  |                                      
|Dilutedas reported                                                                                                                 |  | $                                     | 0.07 |   |      | $ | 0.13  |  
|Dilutedpro forma                                                                                                                   |  | $                                     | 0.06 |   |      | $ | 0.10  |  



- 9 -



---

##### Table of Contents

Note 3 - Revenues



Device revenues include revenues derived from a combination of the Companys devices such as Inovoject® system lease fees, Inovoject® system sales, Egg Remover® fees, Egg Remover® sales, Vaccine Saver® fees, Vaccine Saver® sales and Inovoject® system distributor royalties. Product sales include sales of Bursaplex®, the Companys in ovo infectious bursal disease vaccine, and may include Newplex, the Companys
in ovo Newcastle disease vaccine. The item other revenue includes revenues derived from contract research and development, grant sources and other minor products.



Note 4  Plant and Equipment



Plant and equipment are recorded at cost. Depreciation is computed principally by using
straight-line methods over the estimated useful lives of the assets placed in service, generally three to seven years. The Companys total depreciation expense for the six-months ended June 30, 2005 and 2004, including devices, plant and
equipment was $3.0 million and $2.8 million, respectively. Plant and Equipment, at cost, consist of (in thousands):



|                                           |  |               |         |   |                  |   |        |  
|------------------------------------------ |  | ------------- | ------- | - | ---------------- | - | ------ | -
|(*unaudited)                               |  | June 30,2005* |         |   | December 31,2004 |  
|Plant and equipment                        |  |               |         |   |                  |   |        |  
|Manufacturing buildings and equipment      |  | $             | 980     |   |                  | $ | 745    |  
|Construction in progress                   |  |               | 12,934  |   |                  |   | 12,063 |  
|Leasehold improvements                     |  |               | 5,589   |   |                  |   | 5,529  |  
|Furniture, office and lab equipment, other |  |               | 8,679   |   |                  |   | 8,542  |  
|Vehicles                                   |  |               | 2,254   |   |                  |   | 2,074  |  
|                                           |  |               |         |   |                  |   |        |  
|Total Plant and equipment                  |  | $             | 30,436  |   |                  | $ | 28,953 |  
|Less: accumulated depreciation             |  |               | (10,445 | ) |                  |   | (9,704 | )
|                                           |  |               |         |   |                  |   |        |  
|Net Plant and equipment                    |  | $             | 19,991  |   |                  | $ | 19,249 |  
|                                           |  |               |         |   |                  |   |        |  



Note
5  Intangible Assets



Costs incurred to acquire exclusive licenses of
U.S. patents, to apply for and obtain U.S. patents on internally developed technology and in some cases to bring patent infringement lawsuits are capitalized and amortized using the straight-line method. Exclusive license agreements are amortized
over the period of the license. Patents are amortized over the shorter of the useful or legal life of the patent. Trademarks and Goodwill are not amortized, but analyzed for impairment annually. In the second quarter 2005, approximately $0.4 million
of expenses related to patent infringement lawsuits were capitalized. As of June 30, 2005, an aggregate of $ 1.5 million of expenses related to patent infringement lawsuits are capitalized. If the lawsuits covered by these expenses are not resolved
in the Companys favor, either via settlement or judgment by the applicable court, the capitalized cost will be expensed in future periods. In addition, costs incurred to obtain patents on internally developed technology could be expensed in
future periods if the Company decides to abandon a patent application



- 10 -



---

##### Table of Contents

or a patent is denied. The Companys total amortization expense of intangible assets for the six-month periods ended
June 30, 2005 and 2004 was less than $0.1 million for both periods. Net intangible assets consist of (in thousands):



|                                      |  |               |       |                  |   |      
|------------------------------------- |  | ------------- | ----- | ---------------- | - | -----
|(*unaudited)                          |  | June 30,2005* |       | December 31,2004
|Intangible assets                     |  |               |       |                  |   |      
|Patents and exclusive patent licenses |  | $             | 4,012 |                  | $ | 3,189
|Goodwill                              |  |               | 613   |                  |   | 655  
|Trademarks                            |  |               | 149   |                  |   | 140  
|Other intangibles                     |  |               | 42    |                  |   | 41   
|                                      |  |               |       |                  |   |      
|Net intangible assets                 |  | $             | 4,816 |                  | $ | 4,025
|                                      |  |               |       |                  |   |      



Note
6 - Income Tax Expense



The reported tax rate for second quarter 2005
was 14% in comparison to the 46% reported tax rate for second quarter 2004. The reported tax rate for six-months ended June 30, 2005 was 27% in comparison to the 41% reported tax rate for the same period in 2004. The reported tax rate for second
quarter 2005 and the six-months ended June 30, 2005 decreased over the same periods in 2004 due primarily to the tax benefit of $0.5 million recorded from the filing of amended tax returns for 2001 and 2002 in the second quarter of 2005. The returns
were amended to reflect the Companys claim for extraterritorial income exclusion. The filings of these amended returns represent discrete events that provided the Company tax benefits in the second quarter of 2005. The reported tax rates for
the second quarter 2005 and the six-months ended June 30, 2005 would have been 48% and 47%, respectively, if the tax returns were not amended.



In the second quarter of 2005, withholding taxes accounted for 7 percentage points of the 14% tax rate, and U.S. and non-U.S. income taxes represented the remaining 7
percentage points. In the same period of 2004, the 46% reported tax rate included 7 percentage points of withholding tax and 39 percentage points due to income taxes. Withholding taxes are assessed on revenues in non-U.S. markets, regardless of
income taxable position.



In the first half of 2005, withholding taxes
accounted for 12 percentage points of the 27% tax rate, and U.S. and non-U.S. income taxes represented the remaining 15 percentage points. In the same period of 2004, the 41% reported tax rate included 7 percentage points of withholding tax and 34
percentage points due to income taxes.



Note 7
- Net Income Per Share



Basic net income per share was determined by dividing
net income available to common shareholders by the weighted average number of common shares outstanding during each period presented. Diluted net income per share reflects the potential dilution that could occur assuming conversion or exercise of
all convertible securities and all issued and unexercised stock options with exercise prices that were less than the market price of Embrexs stock (i.e., in-the-money stock options). The dilutive effect of unexercised stock options
is calculated using the Treasury Stock Method.



The following table sets forth
the computation of basic and diluted net income per share (in thousands, except per share amounts):



|                                                                                                           |  |                                      |       |                                    |   |       |  |      |       |  |   |      
|---------------------------------------------------------------------------------------------------------- |  | ------------------------------------ | ----- | ---------------------------------- | - | ----- |  | ---- | ----- |  | - | -----
|                                                                                                           |  | Three Months EndedJune 30(unaudited) |       | Six Months EndedJune 30(unaudited)
|                                                                                                           |  | 2005                                 |       | 2004                               |   | 2005  |  | 2004
|Numerator:                                                                                                 |  |                                      |       |                                    |   |       |  |      |       |  |   |      
|Net Income                                                                                                 |  | $                                    | 1,246 |                                    | $ | 806   |  | $    | 1,856 |  | $ | 1,915
|                                                                                                           |  |                                      |       |                                    |   |       |  |      |       |  |   |      
|Denominator:                                                                                               |  |                                      |       |                                    |   |       |  |      |       |  |   |      
|Denominator for basic net income per shareweighted-average                                                |  |                                      | 7,964 |                                    |   | 7,960 |  |      | 7,950 |  |   | 7,997
|Effect of Dilutive Securities:                                                                             |  |                                      |       |                                    |   |       |  |      |       |  |   |      
|Stock Options and Restricted Stock Grants                                                                  |  |                                      | 314   |                                    |   | 307   |  |      | 325   |  |   | 311  
|Denominator for diluted net income per shareadjusted weighted-average shares and assumed option exercises |  |                                      | 8,278 |                                    |   | 8,268 |  |      | 8,275 |  |   | 8,308
|                                                                                                           |  |                                      |       |                                    |   |       |  |      |       |  |   |      
|Basic net income per share                                                                                 |  | $                                    | 0.16  |                                    | $ | 0.10  |  | $    | 0.23  |  | $ | 0.24 
|                                                                                                           |  |                                      |       |                                    |   |       |  |      |       |  |   |      
|Diluted net income per share                                                                               |  | $                                    | 0.15  |                                    | $ | 0.10  |  | $    | 0.22  |  | $ | 0.23 
|                                                                                                           |  |                                      |       |                                    |   |       |  |      |       |  |   |      



- 11 -



---

##### Table of Contents

Note 8 - Comprehensive Income



FASB Statement No. 130, Reporting Comprehensive Income (SFAS 130)
establishes standards for reporting and display of comprehensive income and its components in the financial statements. In accordance with SFAS 130, the Company has determined total comprehensive income, net of tax, for the three months ended June
30, 2005 and 2004 to be $1.5 million and $0.5 million, respectively. For the six months ended June 30, 2005 and 2004, the Companys total comprehensive income, net of tax, is determined to be $2.1 million and $1.7 million, respectively. The
Companys total comprehensive income represents net income plus the after-tax effect of foreign currency translation adjustments for the periods presented as summarized below (in thousands):



|                                 |  |                                      |       |      |                                    |      |      |  |      |       |  |   |       |  
|-------------------------------- |  | ------------------------------------ | ----- | ---- | ---------------------------------- | ---- | ---- |  | ---- | ----- |  | - | ----- | -
|                                 |  | Three Months EndedJune 30(unaudited) |       |      | Six Months EndedJune 30(unaudited) |     
|                                 |  | 2005                                 |       | 2004 |                                    |      | 2005 |  | 2004 |      
|Net Income                       |  | $                                    | 1,246 |      | $                                  | 806  |      |  | $    | 1,856 |  | $ | 1,915 |  
|Currency Translation Adjustments |  |                                      | 291   |      |                                    | (325 | )    |  |      | 224   |  |   | (227  | )
|                                 |  |                                      |       |      |                                    |      |      |  |      |       |  |   |       |  
|Comprehensive Income             |  | $                                    | 1,537 |      | $                                  | 481  |      |  | $    | 2,080 |  | $ | 1,688 |  
|                                 |  |                                      |       |      |                                    |      |      |  |      |       |  |   |       |  



Note
9 - Segments



The Company operates in a single segment. The table below
presents the Companys operations by geographic area (in thousands):



|                             |  |                           |        |                         |   |        |  |        |        |  |   |       
|---------------------------- |  | ------------------------- | ------ | ----------------------- | - | ------ |  | ------ | ------ |  | - | ------
|                             |  | Three Months EndedJune 30 |        | Six Months EndedJune 30
|(* unaudited)                |  | 2005 *                    |        | 2004 *                  |   | 2005 * |  | 2004 *
|U.S. Revenue:                |  |                           |        |                         |   |        |  |        |        |  |   |       
|Device Revenues              |  | $                         | 8,317  |                         | $ | 8,053  |  | $      | 16,351 |  | $ | 15,759
|Product Sales                |  |                           | -0-    |                         |   | 5      |  |        | -0-    |  |   | 11    
|Other Revenues               |  |                           | 96     |                         |   | 94     |  |        | 210    |  |   | 236   
|                             |  |                           |        |                         |   |        |  |        |        |  |   |       
|Total United States Revenues |  | $                         | 8,413  |                         | $ | 8,152  |  | $      | 16,561 |  | $ | 16,006
|                             |  |                           |        |                        
|International Revenue:       |  |                           |        |                         |   |        |  |        |        |  |   |       
|Device Revenues              |  | $                         | 3,854  |                         | $ | 2,999  |  | $      | 7,743  |  | $ | 6,794 
|Product Sales                |  |                           | 724    |                         |   | 555    |  |        | 1,423  |  |   | 841   
|Other Revenues               |  |                           | 27     |                         |   | 21     |  |        | 54     |  |   | 42    
|                             |  |                           |        |                         |   |        |  |        |        |  |   |       
|Total International Revenues |  | $                         | 4,605  |                         | $ | 3,575  |  | $      | 9,220  |  | $ | 7,677 
|                             |  |                           |        |                        
|Consolidated Revenues        |  | $                         | 13,018 |                         | $ | 11,727 |  | $      | 25,781 |  | $ | 23,683
|                             |  |                           |        |                         |   |        |  |        |        |  |   |       



Total
Assets:



|              |  |                 |        |                  |   |       
|------------- |  | --------------- | ------ | ---------------- | - | ------
|              |  | June 30, 2005 * |        | December 31,2004
|United States |  | $               | 48,354 |                  | $ | 48,613
|International |  |                 | 15,259 |                  |   | 13,967
|              |  |                 |        |                  |   |       
|Total         |  | $               | 63,613 |                  | $ | 62,580
|              |  |                 |        |                  |   |       



- 12 -



---

##### Table of Contents

Note 10 - Debt



The Company obtained a $9.0 million construction/term loan from its bank, Branch Banking and Trust Company (BB&T), in August
2003, to be used for construction and equipping of Embrex Poultry Health, LLC, the Companys Inovocox vaccine manufacturing facility located in Scotland County, North Carolina. The interest rate of the loan is based on the one-month LIBOR
rate plus 1.65%. The loan has a term of 138 months or 11.5 years with payments of interest only for the first 18 months. Principal repayment on the loan began in March 2005 at the end of the interest only period and equal monthly installments of
principal plus interest are payable over the remainder of the loan term. At June 30, 2005, $8.8 million of the construction/term loan was outstanding.



Note 11  Commitments and Contingencies



The Company has certain contractual obligations due to mortgage financing of the Inovocox manufacturing facility, capital leases, operating leases related to office
and storage space rentals and purchase obligations related to the manufacturing of devices, serum and vaccines and the purchase of other miscellaneous supplies. The terms of these obligations vary from less than a year to 10 years.



The Company is engaged in certain legal and administrative proceedings incidental to its
normal business activities. While it is not possible to determine the ultimate outcome of those actions, in the opinion of management after discussion with legal counsel, it is unlikely that the outcome of such litigation and other proceedings will
have a material adverse effect on the results of the Companys operations or its financial position, except that capitalized costs related to lawsuits could be expensed in future periods. See Note 5, Intangible Assets above.



The Company operates in multiple tax jurisdictions and significant judgment is
required in determining its worldwide provision for income taxes. In the ordinary course of a global business, there are many transactions for which the ultimate tax outcome is uncertain. Although the Company believes its approach to determining its
various tax provisions is reasonable, no assurance can be given that the final outcome will not be materially different than that which is reflected in the Companys historical income tax provision and accruals upon review by taxing
authorities. Management believes that adequate amounts of tax and related interest and penalties, if any, have been reserved for any adjustments that may result from years open to examination from taxing authorities. As of June 30, 2005, $1.3
million has been reserved.



- 13 -



---

##### Table of Contents

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations



FORWARD-LOOKING STATEMENTS



Information set forth in this Quarterly Report on Form 10-Q contains various forward looking statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements represent the Companys judgment concerning the future and are subject to risks and uncertainties that could cause the Companys actual operating results
and financial position to differ materially. Such forward looking statements can be identified by the use of forward-looking terminology such as may, will, expect, plan, intend,
target, anticipate, estimate, believe, or continue, or the negative thereof or other variations thereof or comparable terminology.



The Company cautions that any such forward-looking statements include statements with respect
to future products, services, markets and financial results. These statements involve risks and uncertainties that could cause actual results to differ materially. Risks include without limitation the degree of growth in the poultry industry in the
United States and globally, competition arising within the United States and elsewhere, possible decreases in production by our customers, avian disease outbreaks in domestic and/or global markets, market acceptance and cost of expansion in new
geographic markets, and the Companys ability to penetrate new markets. Risks also include the degree of market acceptance of new products, such as Newplex, and the ability of the Companys contract manufacturers to support such
products. Additional risks include the complete commercial development of potential future products on a cost effective basis, including Inovocox, and the ability to obtain regulatory approval of products. Such approval is dependent upon a
number of factors, such as results of trials, the discretion of regulatory officials, and potential changes in regulations. Additional information on these risks and other factors that could affect the Companys consolidated financial results
are described in Risk Factors below, and in the Companys other filings with the Securities and Exchange Commission, including the Companys Forms 10-Q, 10-K and 8-K.



The following discussion and analysis should be read in conjunction with the Companys
consolidated financial statements and related notes appearing elsewhere in this report. The notes to the consolidated financial statements include Note 1, which describes the basis for presentation, and Note 2, which describes the Companys
significant accounting policies.



INTRODUCTION



Embrex, the In Ovo Company®, is an
international biotechnology company engaged in the development of innovative in ovo solutions that meet the needs of the global poultry industry. The Company derives most of its global revenues from fees for the number of eggs processed by
its Inovoject® systems. Other revenue sources for the Company come from lease fees related to its Egg Remover® systems and Vaccine Saver® option installations. In addition to these sources, the Company may sell each of these devices to
distributors under special circumstances in selected countries and to human flu vaccine manufacturers. Revenues from these sources are categorized as device revenues in the Companys financial statements. Another source of revenue for the
Company is product sales, which currently consist of sales of Bursaplex®, an in ovo vaccine for infectious bursal disease, and Newplex, an in ovovaccine for Newcastle disease. The Company also derives some revenues from
contract research and development, grant sources and other minor products. The Companys cost of revenues is primarily attributable to the costs of supporting the Companys devices at customer locations around the world. These costs
include the labor, travel and parts necessary to ensure proper biological and mechanical operation and maintenance of Embrexs devices located at hatcheries of the Companys customers. These costs also include associated depreciation,
sales and property tax expenses. The Company has also built the Embrex Poultry Health, LLC (Embrex Poultry Health or EPH) vaccine manufacturing facility. Subject to product and plant facility approval by the United States Department of
Agriculture (USDA), the facility will be used to produce Inovocox, an in ovo vaccine for the control of coccidiosis.



- 14 -



---

##### Table of Contents

RESULTS OF OPERATIONS



Three Months Ended June 30, 2005 and 2004



CONSOLIDATED NET INCOME



|                                                |  |                                        |        |      |   |        |  |   |        |   |  |    |  
|----------------------------------------------- |  | -------------------------------------- | ------ | ---- | - | ------ |  | - | ------ | - |  | -- | -
|                                                |  | Three Months Ended June 30 (unaudited) |       
|(dollars in thousands except per share amounts) |  | 2005                                   |        | 2004 |   | Change |  |   | Change |  
|Total Revenue                                   |  | $                                      | 13,018 |      | $ | 11,727 |  | $ | 1,291  |   |  | 11 | %
|Gross Profit                                    |  | $                                      | 7,531  |      | $ | 6,953  |  | $ | 578    |   |  | 8  | %
|Operating Income                                |  | $                                      | 1,372  |      | $ | 1,407  |  | $ | (35    | ) |  | -2 | %
|Net Income                                      |  | $                                      | 1,246  |      | $ | 806    |  | $ | 440    |   |  | 55 | %
|Earnings per share  basic                      |  |                                        | 0.16   |      | $ | 0.10   |  | $ | 0.06   |   |  | 60 | %
|Earnings per share  diluted                    |  |                                        | 0.15   |      | $ | 0.10   |  | $ | 0.05   |   |  | 50 | %



Consolidated net income for the second
quarter of 2005 increased to $1.2 million as compared to the second quarter of 2004 net income of $0.8 million. Diluted earnings per share were $0.15 for second quarter 2005 and $0.10 for the same period in 2004. The increase in second quarter 2005
net income as compared to the same period in 2004 was primarily due to the $0.5 million adjustment for validation costs of USDA pre-licensing serials of the Inovocox vaccine, in addition to a $0.5 million decrease in income tax expense in
connection with a lower reported tax rate related to amended tax returns. See Income Tax Expense below.



OUTSTANDING SHARES



|                                            |  |                                        |  |       |  |        |  |        |  
|------------------------------------------- |  | -------------------------------------- |  | ----- |  | ------ |  | ------ | -
|                                            |  | Three Months Ended June 30 (unaudited) | 
|(in thousands except percentages)           |  | 2005                                   |  | 2004  |  | Change |  | Change |  
|Basic Weighted Average Shares Outstanding   |  | 7,964                                  |  | 7,960 |  | 4      |  | 0.0    | %
|Diluted Weighted Average Shares Outstanding |  | 8,278                                  |  | 8,268 |  | 10     |  | 0.1    | %



The basic weighted average shares
outstanding increased 4 thousand shares, or less than 1%, from second quarter 2004 to the same period in 2005. The diluted weighted average shares outstanding increased by 10 thousand shares, or less than 1%, in the second quarter of 2005 compared
to the same period in 2004. These increases are primarily attributable to stock option exercises and the award of restricted stock grants, offset partially by common stock repurchases in the last two quarters of 2004.



CONSOLIDATED REVENUES



|                       |  |                                        |        |      |   |        |  |        |       |  |    |  
|---------------------- |  | -------------------------------------- | ------ | ---- | - | ------ |  | ------ | ----- |  | -- | -
|                       |  | Three Months Ended June 30 (unaudited) |       
|(dollars in thousands) |  | 2005                                   |        | 2004 |   | Change |  | Change |      
|Device revenues        |  | $                                      | 12,172 |      | $ | 11,052 |  | $      | 1,120 |  | 10 | %
|Product sales          |  |                                        | 724    |      |   | 560    |  |        | 164   |  | 29 | %
|Other revenues         |  |                                        | 122    |      |   | 115    |  |        | 7     |  | 6  | %
|                       |  |                                        |        |      |   |        |  |        |       |  |    |  
|Total revenues         |  | $                                      | 13,018 |      | $ | 11,727 |  | $      | 1,291 |  | 11 | %
|                       |  |                                        |        |      |   |        |  |        |       |  |    |  



- 15 -



---

##### Table of Contents

Consolidated revenues for the second quarter of 2005 totaled $13.0 million, representing an increase of 11% over revenues
of $11.7 million for the same period in 2004.



The 2005 second quarter device
revenues include device lease fees derived from single- and multi-year contracts, and paid trials. These recurring fees generally contribute more than 90% of the device revenue in most quarters. In the second quarter of 2005, recurring device lease
fees increased 9% or $1.0 million more than the second quarter of 2004. The increase in recurring device lease fees is primarily due to an increase in the Inovoject® system customer base, particularly in Latin America, as well as additional Egg
Remover® installations. Device revenues also include sales of Inovoject® and Egg Remover® systems to distributors and human flu vaccine manufacturers. The sporadic nature of Inovoject® and Egg Remover® system sales to
distributors and human flu vaccine companies may cause variability in revenue and gross profit on an annual and quarterly basis. For the second quarter of 2005 this variability resulted in a $0.1 million increase in device sales when compared to the
second quarter of 2004. Overall, device revenues totaled $12.2 million for the second quarter of 2005 compared to $11.1 million for the same period in 2004, representing a 10% increase year over year.



Product sales consisted of revenues from sales of Bursaplex®, the Companys proprietary vaccine for avian infectious bursal disease
(IBD). Bursaplex®is a product which uses the Companys AAC technology
(antigen-antibody complex) technology. To date, approval to sell Bursaplex® has been received in 30 countries and is pending in four countries. Currently, Bursaplex® vaccine is being marketed in most of the countries where regulatory
approval has been obtained. Regulatory approvals are being sought in various Latin American, Middle Eastern and Asian markets for in ovo and post-hatch use of Bursaplex® vaccine.



Product sales increased 29% to $0.7 million in the 2005 second quarter as compared to $0.6
million for the same period in 2004, due to higher sales of Bursaplex® in the Asian and North American markets. Despite second quarter 2005 increases in product sales, the Company continues to have a concern that the ongoing uncertainty of challenging conditions, primarily in the Asian
market, may continue for the rest of 2005. This concern is based on the ongoing, yet less numerous, avian influenza outbreaks that may disrupt poultry production levels, as well as consumption in, and exports from, the region. This may also result
in decreased injection activity. Embrex will continue to monitor developments and intends to take appropriate steps as necessary.



Other revenue, which consists mainly of contract research and development, grant sources and other minor products, increased 6% or $7 thousand for second quarter 2005 in
comparison to the same period of 2004. The 2005 grant revenue derives from funding from miscellaneous collaborative and development work. The 2004 grant revenue derives primarily from federal government Small Business Innovation Research
(SBIR) funding for device development work and other miscellaneous grants.



- 16 -



---

##### Table of Contents

COST OF REVENUE



Gross margin decreased one percentage point to 58% for second quarter in 2005 compared to 59% for the same period of 2004. This is primarily due to changes in the
Companys revenue mix and regional mix, which includes higher product sales and additional recurring device lease fees, particularly in Latin America, as well as higher material costs. Inflationary pressure from the increase in the cost of
stainless steel resulted in an increase in the cost of parts used for maintaining the Companys devices and depreciation expenses due to increased capital cost for new devices. These increases could continue to cause gross margins to decrease
in the future. Also, downward pressure on device lease fees, upward changes in other input costs, regional and product mix could cause gross margins to decrease in the future.



OPERATING EXPENSES



|                         |  |                                        |       |      |   |        |  |   |        |   |  |     |  
|------------------------ |  | -------------------------------------- | ----- | ---- | - | ------ |  | - | ------ | - |  | --- | -
|                         |  | Three Months Ended June 30 (unaudited) |      
|(dollars in thousands)   |  | 2005                                   |       | 2004 |   | Change |  |   | Change |  
|General & Administrative |  | $                                      | 2,694 |      | $ | 2,302  |  | $ | 392    |   |  | 17  | %
|Sales & Marketing        |  |                                        | 1,216 |      |   | 689    |  |   | 527    |   |  | 76  | %
|Research & Development   |  |                                        | 2,249 |      |   | 2,555  |  |   | (306   | ) |  | -12 | %
|                         |  |                                        |       |      |   |        |  |   |        |   |  |     |  
|Total Operating Expenses |  | $                                      | 6,159 |      | $ | 5,546  |  | $ | 613    |   |  | 11  | %
|                         |  |                                        |       |      |   |        |  |   |        |   |  |     |  



Operating expenses totaled $6.2
million for the second quarter of 2005 compared to $5.5 million for the same period of 2004. The contributing factors are described below.



General and administrative (G&A) expenses were $2.7 million for the second quarter 2005, an increase of $0.4 million over the same period of 2004. This is
primarily due to increases in staff-related and third-party expenses to support business growth, restricted stock expense, legal fees and accounting fees related to Sarbanes-Oxley Act compliance.



Sales & Marketing expenses were $1.2 million during second quarter 2005, an increase of
76% or $0.5 million over the same period in 2004. The expense increase was due to growth of the Global Marketing group to support pre-launch activities of Inovocox, as well as the continued support of existing products. Additionally, sales and marketing expenses that were previously
allocated to cost of revenues in 2004 have been retained in sales and marketing expenses in 2005 due to departmental reorganization.



Research & Development (R&D) expenses decreased $0.3 million or 12% in comparison to second quarter 2004 expenses. The Companys overall research
and development expenses reflect expenditures incurred in three distinct departments:





The first of these, R&D, is responsible for expenditures associated with the work on our product portfolio, particularly Newplex
vaccine and Inovocox, the in ovo coccidiosis vaccine. R&D expenses remained the same for both second quarter 2005 and 2004 at $1.2 million.



The second of these, Global Product Development & Supply (GPDS), is responsible for development and testing of commercial machine devices and supply of
biological products. GPDS expenses for second quarter 2005 were $0.7 million and remained unchanged from second quarter 2004. This group has also had responsibility for development and commercial testing related to the Gender Sort project. Going
forward, the Company expects a reduction in the R&D effort related to the Gender Sort project as a result of a recent decision to scale back on the project.



- 17 -



---

##### Table of Contents

The third is Engineering and Manufacturing, which makes design modifications and improvements to the Inovoject® and
Egg Remover® systems, as well as the Vaccine Saver® option. Beginning in 2004, start-up manufacturing costs associated with Embrex Poultry Health were captured in Engineering and Manufacturing expenses. Operating expenses for this department
decreased from $0.6 million for second quarter 2004 to $0.3 million for second quarter 2005. This decrease occurred in connection with validation costs of the USDA pre-licensing serials for Inovocox vaccine that were capitalized in the second
quarter of 2005 for the Embrex Poultry Health facility.



OTHER INCOME AND EXPENSE



Net other
income remained unchanged from second quarter 2004 to 2005 at $0.1 million.



Interest income totaled $42 thousand for second quarter 2005, a $22 thousand increase over the same period in 2004. Interest expense totaled $19 thousand, a $15 thousand increase in comparison to the same period in 2004. Interest costs of
$105 thousand and $50 thousand related to the term loan for construction of Embrex Poultry Health are not reflected in the 2005 and 2004 interest expense totals, respectively, as such interest costs are being capitalized as part of the construction
cost of the facility.



INCOME TAX
EXPENSE



Income taxes totaled $0.2 million for second quarter 2005, a $0.5
million decrease from $0.7 million for the same period in 2004. The reported tax rate for 2005 second quarter was 14% in comparison to the 46% reported tax rate of second quarter 2004. The income tax expense decreased in 2005 due primarily to the
$0.5 million tax benefit recorded in the second quarter related to filing of amended tax returns for 2001 and 2002. The returns were amended to reflect the Companys claim for the extraterritorial income exclusion.



Six Months Ended June 30, 2005 and 2004



CONSOLIDATED NET INCOME





|                                                |  |                                      |        |      |   |        |  |   |        |   |  |     |  
|----------------------------------------------- |  | ------------------------------------ | ------ | ---- | - | ------ |  | - | ------ | - |  | --- | -
|                                                |  | Six Months Ended June 30 (unaudited) |       
|(dollars in thousands except per share amounts) |  | 2005                                 |        | 2004 |   | Change |  |   | Change |  
|Total Revenue                                   |  | $                                    | 25,781 |      | $ | 23,683 |  | $ | 2,098  |   |  | 9   | %
|Gross Profit                                    |  | $                                    | 14,801 |      | $ | 14,073 |  | $ | 728    |   |  | 5   | %
|Operating Income                                |  | $                                    | 2,338  |      | $ | 3,131  |  | $ | (793   | ) |  | -25 | %
|Net Income                                      |  | $                                    | 1,856  |      | $ | 1,915  |  | $ | (59    | ) |  | -3  | %
|Earnings per share  basic                      |  | $                                    | 0.23   |      | $ | 0.24   |  | $ | (0.01  | ) |  | -4  | %
|Earnings per share  diluted                    |  | $                                    | 0.22   |      | $ | 0.23   |  | $ | (0.01  | ) |  | -4  | %



Consolidated net income for the first
six months of 2005 remained essentially unchanged at $1.9 million in comparison to the same period in 2004. Diluted earnings per share were $0.22 for the first half of 2005 and $0.23 for the same period in 2004.



- 18 -



---

##### Table of Contents

OUTSTANDING SHARES





|                                            |  |                                      |  |       |  |        |   |  |        |  
|------------------------------------------- |  | ------------------------------------ |  | ----- |  | ------ | - |  | ------ | -
|                                            |  | Six Months Ended June 30 (unaudited) | 
|(in thousands except percentages)           |  | 2005                                 |  | 2004  |  | Change |   |  | Change |  
|Basic Weighted Average Shares Outstanding   |  | 7,950                                |  | 7,997 |  | (47    | ) |  | -0.6   | %
|Diluted Weighted Average Shares Outstanding |  | 8,275                                |  | 8,308 |  | (33    | ) |  | -0.4   | %



The weighted average shares
outstanding decreased 47 thousand shares or less than 1% from 2004 to 2005. The decrease is primarily attributable to common stock repurchases by the Company during the last two quarters of 2004, partially offset by stock option exercises and the
award of restricted stock grants.



The diluted weighted average shares
outstanding decreased by 33 thousand shares, or less than 1%, in the first half of 2005 compared to the same period in 2004. This decrease is primarily attributable to common stock repurchases by the Company in the last two quarters of 2004. In
addition, the average closing price of the Companys stock decreased from $12.18 for the first six months of 2004 to $11.74 for the same period of 2005, resulting in fewer dilutive stock options in 2005. The lower share price in 2005 decreased
the number of outstanding stock options with exercise prices that were less than the market price of Embrexs stock (i.e., in-the-money stock options). Because only in-the-money stock options are counted in computing diluted
weighted average shares outstanding, the lower average closing price for the Companys common stock in 2005 as compared to 2004 resulted in fewer dilutive stock options being taken into account in 2005.



CONSOLIDATED REVENUES





|                       |  |                                      |        |      |   |        |  |   |        |   |  |    |  
|---------------------- |  | ------------------------------------ | ------ | ---- | - | ------ |  | - | ------ | - |  | -- | -
|                       |  | Six Months Ended June 30 (unaudited) |       
|(dollars in thousands) |  | 2005                                 |        | 2004 |   | Change |  |   | Change |  
|Device revenues        |  | $                                    | 24,094 |      | $ | 22,553 |  | $ | 1,541  |   |  | 7  | %
|Product sales          |  |                                      | 1,423  |      |   | 852    |  |   | 571    |   |  | 67 | %
|Other revenues         |  |                                      | 264    |      |   | 278    |  |   | (14    | ) |  | -5 | %
|                       |  |                                      |        |      |   |        |  |   |        |   |  |    |  
|Total revenues         |  | $                                    | 25,781 |      | $ | 23,683 |  | $ | 2,098  |   |  | 9  | %
|                       |  |                                      |        |      |   |        |  |   |        |   |  |    |  



Consolidated revenues for the first
half of 2005 totaled $25.8 million, representing an increase of 9% over revenues of $23.7 million for the same period in 2004.



In the first half of 2005, device lease fees increased 9% or $2.0 million as compared to the first half of the prior year. The increase in device fees is primarily due to
an increase in the Inovoject® system customer base, as well as additional Egg Remover® installations. Device revenues also include sales of Inovoject® and Egg Remover® systems to distributors and human flu vaccine manufacturers. The
sporadic nature of Inovoject® and Egg Remover® system sales to distributors and human flu vaccine companies may cause variability in revenue and gross profit on an annual and quarterly basis. For the first half of 2005 this variability
resulted in a $0.5 million decrease in device sales when compared to the first half of 2004. Overall, device revenues totaled $24.1 million for the first half of 2005 compared to $22.6 million for the same period in 2004, representing a 7% increase
year over year.



- 19 -



---

##### Table of Contents

Product sales increased 67% to $1.4 million in the first half of 2005 as compared to $0.9 million for the same period in
2004, due to increased Bursaplex® sales in Asia that occurred as the effects of avian influenza outbreaks subsided and poultry production in the region increased.



Other revenue remained essentially unchanged from the first six months of 2004 to the same period of 2005. The majority of Other Revenue
consists of funding from contract research and development, grant sources and other minor products. The 2005 grant revenue derives from funding from miscellaneous collaborative and development work. The 2004 grant revenue derives primarily from SBIR
funding for device development work and other miscellaneous grants.



COST OF
REVENUE



Gross margin decreased from 59% in the first six months of 2004
to 57% for the same period of 2005. This is primarily due to changes in the Companys revenue mix and regional mix, which includes higher product sales, additional recurring device lease fees, particularly in Latin America, as well as lower
device sales. Since device sales have a higher gross margin than the Companys other revenue sources, the lower device sales in first half 2005 contributed to the reduction in gross margin. In addition, inflationary pressure associated with the
increase in the cost of stainless steel resulted in an increase in the material costs used for maintaining the Companys devices and depreciation expenses due to increased capital cost for new devices. These increases could continue to cause
gross margins to decrease in the future. Also, downward pressure on device lease fees, upward changes in other input costs, regional and product mix could cause gross margins to decrease in the future.



OPERATING EXPENSES



|                         |  |                                      |        |      |   |        |  |        |       |  |      |  
|------------------------ |  | ------------------------------------ | ------ | ---- | - | ------ |  | ------ | ----- |  | ---- | -
|                         |  | Six Months Ended June 30 (unaudited) |       
|(Dollars in thousands)   |  | 2005                                 |        | 2004 |   | Change |  | Change |      
|General & Administrative |  | $                                    | 5,268  |      | $ | 4,854  |  | $      | 414   |  | 9    | %
|Sales & Marketing        |  |                                      | 2,195  |      |   | 1,334  |  |        | 861   |  | 65   | %
|Research & Development   |  |                                      | 5,000  |      |   | 4,754  |  |        | 246   |  | 5    | %
|                         |  |                                      |        |      |   |        |  |        |       |  |      |  
|Total Operating Expenses |  | $                                    | 12,463 |      | $ | 10,942 |  | $      | 1,521 |  | 14.0 | %
|                         |  |                                      |        |      |   |        |  |        |       |  |      |  



Operating expenses totaled $12.5
million for the first six months of 2005 compared to $10.9 million for the same period of 2004. The primary reason for the overall increase was to support growth in Latin American operations and prepare for the Inovocox pre-launch activities. Other factors are described below.



General and administrative (G&A) expenses were $5.3 million for the first
half of 2005, up $0.4 million or 9% compared to the same period of 2004. The increase in G&A expenses over 2004 was primarily due to additional staff-related expenses supporting business growth, as well as a $0.1 million increase in legal fees
relating to patents and Sarbanes-Oxley Act compliance. In addition, expense increases relating to accounting fees for internal controls in compliance with the Sarbanes-Oxley Act, restricted stock expense and additional property taxes related to the
Embrex Poultry Health manufacturing facility contribute to the increase in G&A expenses.



Sales & Marketing expenses for first-half 2005 were $2.2 million, up $0.9 million compared to the same period in 2004. The expense increase was due to growth of the Global Marketing group to support pre-launch
activities of Inovocox, as well as the continued
support of existing products. Additionally, sales and marketing expenses that were previously allocated to cost of revenues in 2004 have been retained in sales and marketing expenses in 2005 due to departmental reorganization.





- 20 -



---

##### Table of Contents

Research & Development (R&D) expenses increased $0.2 million from $4.8 million for the first six
months of 2004 to $5.0 million for the same period of 2005. The increase is principally due to increased staff-related expenses and Gender Sort development work.



OTHER INCOME AND EXPENSE



Net other income increased from $0.1 million for the first half of 2004 to $0.2 million for the same period of 2005. This increase is
primarily due to 2005 currency translation gains.



Interest income totaled $64
thousand and $41 thousand for the first six months of 2005 and 2004, respectively. This increase is primarily due to interest income received for maintaining higher cash balances in countries outside the U.S. that pay higher interest rates.



Interest expense totaled $25 thousand in the first half of 2005 compared to
$16 thousand for the same period of 2004. The increase in interest expense was primarily due to increased usage of the Companys short-term line of credit to help fund working capital and the start-up of Embrex Poultry Health. Interest costs of
$105 thousand and $50 thousand related to the term loan for construction of Embrex Poultry Health are not reflected in the 2005 and 2004 interest expense totals, respectively, as such interest costs are being capitalized as part of the construction
cost of the facility.



INCOME TAX
EXPENSE



Income taxes totaled $0.7 million for the first half of 2005, a
$0.6 million decrease from $1.3 million for the same period in 2004. The reported tax rate for the 2005 first half was 27% in comparison to the 41% reported tax rate for the first half of 2004. The income tax expense was $0.6 million lower in 2005
due primarily to the tax benefit of $0.5 million recorded from the filing of amended tax returns, as well as a decrease of $0.2 million due to the decrease in pre-tax net income as compared to the same period in 2004. The returns were amended to
reflect the Companys claim for the extraterritorial income exclusion in 2001 and 2002. These were partially offset by an income tax expense increase of $0.1 in 2005 due to withholding taxes on increased business activities in non-U.S. markets
as compared to the same period in 2004. Withholding taxes are assessed on revenues in non-U.S. markets, regardless of income taxable position. Lastly, the income tax expense decreased $0.2 million in 2005 due to the decrease in pre-tax net income as
compared to the same period in 2004.



LIQUIDITY AND CAPITAL RESOURCES



At June 30, 2005, the
Companys cash and cash equivalents balances totaled $1.9 million compared to $4.5 million at December 31, 2004. The decrease from 2004 to 2005 is primarily attributable to expenditures of $7.3 million for devices and other capital items, as
well as a $1.5 million reduction in non-debt current liabilities. Investments in patents and other non-current assets used $0.9 million of cash as well. This was partially offset by $5.2 million provided by net income and non-cash items, such as
depreciation and amortization, and a reduction in accounts receivable and other current assets.



During the first six months of 2005, operating activities generated $5.2 million in cash, primarily due to net income, non-cash depreciation, expensing of restricted stock, reductions in accounts receivable and
changes in the deferred tax asset. Investing activities, device purchases and other capital expenditures used $8.2 million. Financing activities provided $0.2 million in connection with the issuance of Common Stock related to stock option exercises
for $0.4 million, partially offset by repayment of $0.2 million of the current portion of the Companys construction/term loan.



The Company obtained a $9.0 million construction/term loan from BB&T in August 2003 that was used for building and equipping the Embrex Poultry Health manufacturing
facility, located in Scotland County, North Carolina. At June 30, 2005, $8.8 million of the construction/term loan was outstanding.



- 21 -



---

##### Table of Contents

The Company has a $6.0 million secured revolving line of credit with BB&T, which may be used for working capital
purposes. The term of this line of credit was extended to May 2006. The line of credit carries an interest rate of the current LIBOR rate plus 1.60%. At June 30, 2005, the Company had no outstanding borrowings under this credit facility.



In August 2002, the Company announced that the Board of Directors authorized a share
repurchase program (the 2002 Repurchase Program) to purchase up to 6% of outstanding shares of Common Stock, or up to approximately 500,000 shares over 17 months, in open market or privately negotiated transactions. In November 2003, the
Board of Directors extended the term of the 2002 Repurchase Program to June 30, 2004. The Company repurchased an aggregate of 455,100 shares of its Common Stock for $5.1 million at an average price of $11.15 per share during the entire term of the
2002 Repurchase Program.



In May 2004, the Company announced that the Board of
Directors authorized a share repurchase program (the 2004 Repurchase Program) to purchase up to 500,000 of outstanding shares of Common Stock through December 2005, in open market or privately negotiated transactions on or after July 1,
2004. During 2004, the Company purchased 44,350 shares of its Common Stock for $0.6 million at an average price of $12.84 per share under the 2004 program. The Company made no share repurchases during the first six months of 2005.



Based on its current operations, management believes that the Companys available cash
and cash equivalents, together with cash flow from operations and its bank line of credit, will be sufficient to meet its cash requirements as these currently exist. However, Embrex may continue to explore additional alternative funding
opportunities with respect to collaborative ventures and product development and will evaluate its cash requirements as appropriate.



RISK FACTORS



If any of the following risks occur, our business, financial condition, or results of operations could be materially adversely affected.



OUR FUTURE GROWTH DEPENDS ON EXPANSION OF INTERNATIONAL REVENUES AND WE WILL BE SUBJECT TO INCREASED RISKS IN THE INTERNATIONAL
MARKETPLACE



We estimate that our Inovoject® system inoculates
approximately 85% of all eggs produced for the U.S. and Canadian broiler poultry markets. Given this market penetration, we expect only limited growth in the number of system installations and only minor system revenue growth in this market.
Additionally, due to our market penetration and the significance of the U.S. and Canadian poultry markets to our revenue, any adverse conditions in these markets could have a material and adverse affect on our revenues. For this reason, we must
expand our device installations and product sales in markets outside the United States and Canada in order to realize revenue growth. In 2004, international sales accounted for 34% of our consolidated revenues. In 2003 and 2002, international sales
accounted for 32% and 31% of our consolidated revenues, respectively. Revenue growth outside the United States and Canada depends on gaining market acceptance of our devices andin ovo administration of vaccine products in markets outside the
United States and Canada to treat prevailing poultry diseases in those markets. Lack of market acceptance of our devices andin ovo products in these markets would materially adversely affect our revenue growth. Our operating expenses
associated with operations outside the United States and Canada have historically been relatively higher that similar costs for operations inside the United States and Canada. Accordingly, we believe that international sales may result in decreased
gross margins for Embrex.



International sales are also subject to a variety of
risks, including risks arising from the following:



| |  |  | exchange rate risks, tariffs, trade barriers and taxes;
| | - |  | -------------------------------------------------------



- 22 -



---

##### Table of Contents

| |  |  | adverse changes in local investment or exchange control regulations, potential restrictions on the flow of international capital, and the possibility of confiscatory taxation, price
controls or the taking or modification of our property rights by a country in the exercise of its sovereignty;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | economic and political conditions beyond our control, including country-specific conditions such as political instability, government corruption and civil unrest;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the risk that current product registrations subject to periodic re-registration in certain foreign countries may not be granted a renewal license due to regulatory changes or other
reasons; and
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | trade restrictions and economic embargoes imposed by the United States and other countries.
| | - |  | -------------------------------------------------------------------------------------------



OUR FUTURE GROWTH ALSO DEPENDS ON THE DEVELOPMENT AND MARKET ACCEPTANCE OF NEW PRODUCTS



In addition to international expansion, we need to develop and market
new products to continue to generate increased revenues and growth of our business. We currently are developing, both independently and in collaboration with others, various products which address poultry health and performance needs. These products
are being designed to be deliveredin ovo through the Inovoject® system or in conjunction with the Inovoject® system, and are in various stages of development. We may increase, decrease or eliminate funding for any product under development at any time depending on our
assessment of its priorities, its available funding, the probability that the product can be successfully commercialized, potential return on investment and other factors. There is no guarantee that any new products will be successfully developed
and marketed. In addition, we have not initiated the regulatory approval process for some of these potential products, and we cannot assure you that regulatory approval will be obtained. Our inability to develop new products or any delay in our
development of them may materially adversely affect our revenue growth. Because of a number of factors, a new product may not reach the market without lengthy delays, if at all. Some of the factors that may affect our development and marketing of
new products include the following:



| |  |  | our research and evaluations of compounds and new technologies may not yield product opportunities;
| | - |  | ---------------------------------------------------------------------------------------------------



| |  |  | potential products may involve extensive and time-consuming clinical trials to demonstrate safety and effectiveness, and the results of such trials are uncertain;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | potential products may require collaborative partners and we may be unable to identify partners or enter into arrangements on terms acceptable to us;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | we may not be able to produce or contract for the manufacture of new products at a cost or in quantities necessary to make them commercially viable;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | domestic and international regulatory approval of these products may not be obtained or may be obtained only with lengthy delays;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------



| |  |  | we may not be able to secure additional financing that may be needed to bring a potential product to market;
| | - |  | ------------------------------------------------------------------------------------------------------------



| |  |  | we may experience unexpected safety, regulatory or efficacy concerns with respect to marketed products, whether or not scientifically justified, leading to adverse public reaction,
product recalls, withdrawals or declining sales;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



- 23 -



---

##### Table of Contents

| |  |  | marketing products developed jointly with other parties may require royalty payments or other payments by us to our co-developers, which may materially adversely affect our
profitability;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | we may be unable to accurately predict market requirements and evolving standards; and
| | - |  | --------------------------------------------------------------------------------------



| |  |  | we may not be able to attract and retain sufficient numbers of qualified development personnel.
| | - |  | -----------------------------------------------------------------------------------------------



We have developed and commercialized two devices that work with the Inovoject® system: the Egg Remover® and Vaccine Saver®. The
Egg Remover® can also be used without an Inovoject® system in specific situations where customers do not need injection services. These two devices have had initial success, however, there is no guarantee that acceptance of these devices
will continue to grow.



Embrex has initiated the United States Department of
Agriculture (USDA) regulatory approval process with respect to ourin ovo coccidiosis vaccine, Inovocox. Although this product has begun the regulatory review process, there is no assurance that USDA approval will be obtained. Marketing this product in
non-U.S. countries will require us to pursue separate approvals from their regulatory agencies. We completed construction of a vaccine manufacturing facility, Embrex Poultry Health, in the first quarter of 2004 to commercially produce the
Inovocox vaccine. Construction costs for Embrex
Poultry Health to date are approximately $12.9 million. In addition to USDA approval for Inovocox, our coccidiosis vaccine manufacturing facility must receive a separate USDA approval to manufacture the Inovocox vaccine. We cannot assure you that the facility will receive USDA approval to manufacture Inovocox. Delays in obtaining either product or manufacturing
facility approvals may materially adversely affect our marketing of, and our ability to receive revenues from, Inovocox. Additionally, even if we receive USDA product and facility approvals, we cannot assure you that Inovocox supplies will be available, be sold in commercial quantities or that product sales
will be sufficient to offset our investment in development of the product and construction of the Inovocox vaccine manufacturing facility.



We have developed and commercialized antigen-antibody complex, or AAC, technology that we use in our Bursaplex® vaccine. Bursaplex® has been sold in commercial
quantities during the past six years, however, there is no assurance that supplies will be available or that the product will continue to be sold in commercial quantities.



In May 2003, the USDA provided regulatory approval of Newplex, ourin ovo Newcastle Disease vaccine, within the United States. Newplex vaccine is also based on AAC technology. We are now seeking regulatory approval for
Newplex in key markets worldwide. Although we
have received approval to sell Newplex in six countries, there is no assurance that other registrations will be granted, supplies will be available, or that Newplex will be sold in commercial quantities.



There can be no assurance that we will successfully complete the development and commercialization of any new products or that such products
if developed and commercialized, will meet revenue and profit expectations.



ECONOMIC FACTORS AFFECTING OUR CUSTOMERS MAY ADVERSELY AFFECT OUR FINANCIAL RESULTS



Our revenues principally come from leases and sales to the poultry industry. If there is a general economic decline in that industry, our operations and financial
condition could be materially and adversely affected. Also, domestic and global economic factors beyond our control may adversely impact our customers and, as a result, our revenues and earnings. Examples of these factors include the following:



| |  |  | fluctuations in the prices of energy and poultry feed;
| | - |  | ------------------------------------------------------



- 24 -



---

##### Table of Contents

| |  |  | disease outbreaks that adversely affect poultry production;
| | - |  | -----------------------------------------------------------



| |  |  | market demand for poultry products, including the supply and pricing of alternative proteins;
| | - |  | ---------------------------------------------------------------------------------------------



| |  |  | costs to comply with applicable laws and regulations, including those relating to environmental protection, food safety, market regulation and genetically modified organisms or
ingredients;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | product recalls and related adverse publicity and consumer reaction;
| | - |  | --------------------------------------------------------------------



| |  |  | access to foreign markets together with foreign economic conditions, including currency fluctuations and trade restrictions; and
| | - |  | --------------------------------------------------------------------------------------------------------------------------------



| |  |  | the extent to which our cost of products and operating expenses increase faster than contractual price adjustments with our customers.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------



For example, if rising poultry feed prices increase the production costs of commercial
poultry producers or a foreign government bans the importation of U.S. chicken, these producers may reduce production. This decreased production could adversely impact our revenues, since a principal component of our revenues are fees charged to
customers for the number of eggs injected or processed by Embrex devices.



WE FACE RISKS OF COMPETITION AND CHANGING TECHNOLOGY



The Inovoject® system uses a process that was patented in the United States by the USDA in 1984. We held the exclusive license to the Sharma Patent until June 2002, when the Sharma Patent expired. With the expiration of the Sharma
Patent, competitivein ovo delivery systems are being developed and marketed. Embrex is aware of four companies that are marketing in ovo injection systems to poultry companies. Although there has not been widespread commercial
acceptance of any of these competing systems, we are aware of direct competition for customers and limited commercial placements by some of these companies. Additionally, the contracts we currently have with several of our customers allow them to
evaluate these competitive systems and products. Competition could result in lower prices for our products, reduced demand for our products, and a corresponding reduction in our ability to recover development, engineering, manufacturing and service
costs. Also, a significant portion of our revenues comes from a relatively small number of customers. If we lose one or more large customers due to competition, our revenues could be significantly lower. Any of these developments could have a
material adverse effect on our business, results of operations and financial condition.



The poultry vaccine business is especially competitive and dominated by a few large companies with an established global presence. In order for us to expand our sales ofin ovo vaccines, these products must be commercially accepted
worldwide and compete effectively against the vaccines of these other companies. Our inability to compete successfully in the poultry vaccine sector could materially adversely affect our revenue growth.



Our competitors and potential competitors include independent companies that specialize in
biotechnology, as well as major agricultural or animal health companies, pharmaceutical companies, chemical companies, universities, and public and private research organizations. Many of these competitors are well established and have substantially
greater marketing, financial, technological and other resources than we have. Competitors may succeed in developing technologies and products that are more effective than any that have been or are being developed by us or that could render our
technology and products obsolete or non-competitive.



- 25 -



---

##### Table of Contents

WE FACE RISKS RELATED TO COMPLIANCE WITH LAWS IMPACTING CORPORATE GOVERNANCE AND FINANCIAL REPORTING STANDARDS



The Sarbanes-Oxley Act of 2002, as well as related new rules and
regulations implemented by the Securities and Exchange Commission, Nasdaq and the Public Company Accounting Oversight Board, have required changes in the corporate governance practices and financial reporting standards for public companies. These
new laws, rules and regulations, including compliance with Section 404 of the Sarbanes-Oxley Act of 2002, have materially increased our legal and financial compliance costs and made many activities more time-consuming and more burdensome. The costs
of compliance with these laws, rules and regulations have adversely affected our financial results. Moreover, we run the risk of non-compliance which could adversely affect our financial condition or results of operations or the trading price of our
stock. For example, when conducting our assessment of internal control over financial reporting pursuant to Section 404 for the fiscal year ended December 31, 2004, we identified a material weakness in our internal controls in the area of accounting
for income taxes. Although we are taking steps to address this material weakness, there is no assurance that we will be successful in remedying the material weakness or preventing future material weaknesses. In addition, if our increased
international revenues in certain markets results in the revenues of certain of our subsidiaries in those markets comprising 10% or more of our consolidated revenues, it will be necessary for those subsidiaries to also implement applicable internal
control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002. There is no assurance that we would be able to implement such internal control over financial reporting on a timely basis. Thus, there is a risk that any
such subsidiary could lack adequate internal control over financial reporting, resulting in a material weakness with respect to Embrexs consolidated internal control over financial reporting.



POULTRY HEALTH AND DISEASE FACTORS AFFECTING OUR CUSTOMERS MAY ADVERSELY AFFECT OUR
FINANCIAL RESULTS



Any widespread poultry health problem or disease
outbreak could have a negative impact on global poultry production. Our revenues and earnings derived from both the U.S. and international poultry industry could be materially and adversely affected. In addition, the emergence of new disease
variants, serotypes and strains in the domestic and/or global markets may reduce the efficacy of our vaccine products and result in reduced revenues and earnings.



WE DO NOT MANUFACTURE MOST OF OUR DEVICES OR ANY OF OUR VACCINE PRODUCTS, AND ARE DEPENDENT ON ONE CONTRACT MANUFACTURER FOR
INOVOJECT® AND EGG REMOVER® DEVICES AND ANOTHER CONTRACT MANUFACTURER FOR AAC PRODUCTION. WE ARE ALSO DEPENDENT ON SINGLE CONTRACT MANUFACTURERS FOR PRODUCTION OF BOTH BURSAPLEX® AND NEWPLEX.



General Risks Associated with Reliance on Contract Manufacturers



We currently do not have facilities for the production of most of our devices and vaccine products. Therefore, we rely principally upon relationships with contract
manufacturers. There can be no assurance that we can maintain manufacture and supply agreements on terms and at costs acceptable to us. We have various relationships with manufacturers and suppliers, including those described below. The loss of any
of these relationships could materially adversely affect our operating results. There are a number of risks associated with our dependence on contract manufacturers, including:



| |  |  | reduced control over delivery schedules;
| | - |  | ----------------------------------------



| |  |  | potential inability to monitor and maintain inventory levels;
| | - |  | -------------------------------------------------------------



| |  |  | reduced control over quality assurance;
| | - |  | ---------------------------------------



- 26 -



---

##### Table of Contents

| |  |  | reduced control over manufacturing yields and costs;
| | - |  | ----------------------------------------------------



| |  |  | potential lack of adequate capacity during periods of unanticipated demand;
| | - |  | ---------------------------------------------------------------------------



| |  |  | limited warranties on products supplied to us;
| | - |  | ----------------------------------------------



| |  |  | increases in prices;
| | - |  | --------------------



| |  |  | reduced control over regulatory efforts;
| | - |  | ----------------------------------------



| |  |  | potential misappropriation of our intellectual property;
| | - |  | --------------------------------------------------------



| |  |  | catastrophic loss of production capacity due to property damage, either man made or by nature;
| | - |  | ----------------------------------------------------------------------------------------------



| |  |  | the loss of these contract manufacturers due to financial circumstances in their respective businesses or their exit from the business lines that manufacture our devices and
products; and
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | minimum purchase requirements, which could result in excessive inventories if the demand for products falls short of such minimum purchase requirements.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------



If our contract manufacturers failed to provide us with an adequate supply of finished
devices or vaccine products, our business would be harmed. We do not have long-term contracts or arrangements with several of our vendors that guarantee product availability or the continuation of particular payment terms. In addition, we are
currently dependent on a single contract manufacturer for several of our key products as described below. Although we believe our relationship with each of the manufacturers is sound, we cannot assure you that we will continue to maintain
relationships with them or that they will continue to exist.



Inovoject®
and Egg Remover® Systems



We rely on Precision Automation Company,
Inc., or Precision, to fabricate all of our Inovoject® and Egg Remover® systems. While other machine fabricators exist and have constructed limited numbers of Inovoject® systems, we do not currently have alternative sources for
production of either the Inovoject® or Egg Remover® systems. If Precision is unable to carry out its manufacturing obligations to our satisfaction, we may be unable to obtain alternative manufacturing, or to obtain such manufacturing on
commercially reasonable terms or on a timely basis. Any delays in the manufacturing process may adversely impact our ability to meet commercial demands for Inovoject® and Egg Remover® system installations and delay receipt of revenues from
those installations.



Vaccines and AAC Technology



We obtain all of our requirements for the active ingredient in AAC technology from Charles
River Laboratories, Inc. through its SPAFAS Avian Products Services Division, or SPAFAS. Under our agreement with SPAFAS, we are required to purchase minimum amounts of AAC-based antigen on an annual basis. The manufacture of AAC must be performed
in licensed facilities and is subject to USDA regulation. The regulatory approvals granted by the USDA for Bursaplex® in January 1997 and for Newplex in May 2003 specifically cover vaccines produced with SPAFAS-manufactured AAC. Although there are other manufacturers that may be capable of
manufacturing AAC, we do not currently have alternative sources for production of AAC.



We obtain all of our requirements for Bursaplex® from Merial Select, Inc., or Select, a Merck and Sanofi-Aventis company, and all of our requirements for Newplex from Lohmann Animal Health International, or LAHI. The manufacture of all vaccine products must be performed in
licensed facilities, under approved regulatory methods. As the USDA licensed manufacturers of record, Select holds the USDA



- 27 -



---

##### Table of Contents

permit for Bursaplex® and LAHI holds the USDA permit for Newplex. Although there are other manufacturers that may be capable of manufacturing avian
viral vaccines, we do not currently have alternative sources for production of either product.



If SPAFAS, Select or LAHI is unable to carry out its respective manufacturing obligations (described above) to our satisfaction, we may be unable to obtain alternative manufacturing, or to obtain such manufacturing on
commercially reasonable terms or on a timely basis. A change of supplier for the Company could materially adversely affect our future operating results due to the time it would take a new supplier to obtain regulatory approval by the USDA of its
production process or manufacturing facilities. Current regulatory approvals in foreign countries are or will be based on product manufactured with AAC as manufactured by SPAFAS or Bursaplex® as manufactured by Select or Newplex as manufactured by LAHI. A change of manufacturer
would result in the need to reapply for regulatory approval in those countries and may lead to suspended sales of that product until new approvals could be secured. Any delays in securing new approvals would have a material adverse effect on our
revenues and growth prospects. We cannot guarantee that we would be able to secure new approvals in every country or that such approvals would be granted in a timely fashion.



WE ARE DEPENDENT ON DISTRIBUTORS IN CERTAIN MARKETS



We market and distribute our devices principally by leasing and licensing the systems directly to hatcheries. In some markets, such as
Japan, we instead rely upon distributors for our devices. We also rely on third parties to market certain of our vaccine products, such as products containing AAC technology, and we may enter into other arrangements in the future. There can be no
assurance that we can maintain these relationships on terms acceptable to us. The loss of any of these relationships could materially adversely affect our operating results. There are a number of risks associated with our dependence on distributors
and other third parties including:



| |  |  | reduced control over regulatory efforts which may delay local regulatory approvals and thus market introduction;
| | - |  | ----------------------------------------------------------------------------------------------------------------



| |  |  | reduced control over marketing and sales efforts and in turn the extent of resulting market penetration or acceptance;
| | - |  | ----------------------------------------------------------------------------------------------------------------------



| |  |  | reduced control over distribution and related customer satisfaction; and
| | - |  | ------------------------------------------------------------------------



| |  |  | potential delays in distribution associated with securing new distributors, including the possible need to seek re-registration in markets where a distributor may hold product
registration, if current relationships are not maintained.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



THE LOSS OF KEY CUSTOMERS COULD ADVERSELY AFFECT OUR FINANCIAL RESULTS



Historically, a significant portion of our revenues has come from a relatively small number of customers. Tyson Foods, Inc. accounted for approximately 18% and 20% of our consolidated 2004 and 2003 revenues,
respectively. During 1997, Tyson extended its contract with Embrex through 2004 and then entered into a short-term contract in May 2005. Our top three customers, including Tyson, accounted for approximately 36% and 37% of our consolidated 2004 and
2003 revenues, respectively. We expect a similar level of customer concentration to continue in future years. The poultry market is highly concentrated, with the largest poultry producers dominating the market. For example, in 2004, Tyson supplied
approximately 22% of all broilers grown in the United States. The concentration of our revenues with these large customers means factors affecting those customers also will impact our revenues and earnings. If we lose a large customer and fail to
add new customers to replace lost revenues, our operating results will be materially and adversely affected. Also, if these customers reduce the number of eggs they incubate at hatcheries, we will receive lower device revenues since our fees are
based on the number of eggs injected.



- 28 -



---

##### Table of Contents

IF WE LOSE THE PROTECTION OF OUR PATENTS AND PROPRIETARY RIGHTS, OUR FINANCIAL RESULTS COULD SUFFER



Importance and Limitations of Patent and Proprietary Rights
Protections



Some of our products and processes used to produce our
products involve proprietary rights, including patents. We own some of the technologies employed in these processes, and some are owned by others and licensed to us. The Inovoject® system utilizes a process that was patented by the USDA in the
United States. We held an exclusive license to the Sharma Patent, which expired in June 2002. We have supplemented the Sharma Patent with additional U.S. and foreign patents and have submitted additional patent applications covering specific design
features of the Inovoject® system, as well as Embrexs Egg Remover® system and Vaccine Saver® option. Our competitors or potential competitors may have filed for or received United States and foreign patents and may obtain
additional patents and proprietary rights relating to in ovo technology, vaccines, uses and/or processes which may compete with our existing products and our products under development. Accordingly, we cannot assure you that our patent
applications will result in patents being issued or that, if issued, the claims under our patents will afford protection against competitors with similar technology. We cannot be sure that others will not obtain patents of different technology that
we would need to license or circumvent in order to practice our inventions. Even though we strive to take appropriate action to protect our intellectual property, there is a risk that competitive systems currently being developed and marketed could
gain acceptance in the United States or elsewhere.



We believe that patent
protection of materials or processes we develop and any products that may result from the research and development efforts of our licensors and us are important to the commercial success of our products. The loss of the protection of these patents
and proprietary rights could materially adversely affect our business and our competitive position in the market. The patent position of companies such as ours generally is highly uncertain and involves complex legal and factual questions. Some of
the reasons for this uncertainty include the following:



| |  |  | To date, no consistent regulatory policy has emerged regarding the breadth of claims allowed in biotechnology patents. Consequently, there can be no assurance that patent
applications relating to our products or technology will result in patents being issued or that, if issued, the patents will afford protection against competitors with similar technology;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Some patent licenses held by us may be terminated upon the occurrence of specified events or become non-exclusive after a specified period;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Companies that obtain patents claiming products or processes that are necessary for or useful to the development of our products could bring legal actions against us claiming
infringement (though we currently are not the subject of any patent infringement claim);
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Issuance of a valid patent does not prevent other companies from using alternative, non-infringing technology so we cannot be sure that any of our patents (or patents issued to
others and licensed to us) will provide significant commercial protection;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | We may not have the financial resources necessary to obtain patent protection in some countries or to enforce any patent rights we may hold;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | The laws of some foreign countries may not protect proprietary rights to the same extent as the laws of the United States, and many companies have encountered significant problems
in protecting their proprietary rights in these foreign countries;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | We may be required to obtain licenses from others to develop, manufacture or market our products. We may not be able to obtain these licenses on commercially reasonable terms, and
we cannot be sure that the patents underlying the licenses will be valid and enforceable; and
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



- 29 -



---

##### Table of Contents

| |  |  | We also rely upon unpatented, proprietary technology, which we may not be able to protect fully if others independently develop substantially equivalent proprietary information or
techniques, improperly gain access to our proprietary technology, or disclose this technology to others.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



We attempt to protect our proprietary materials and processes by relying on trade secret laws and non-disclosure and confidentiality agreements with our employees and
other persons with access to our proprietary materials or processes or who have licensing or research arrangements with us. We plan to continue to use these protections in the future but we cannot be sure that these agreements will not be breached
or that we would have adequate remedies for any breach. Even with these protections, others may independently develop or obtain access to these materials or processes, which may materially adversely affect our competitive position.



If we are sued for infringing the patent or other proprietary rights of a third party, we
could incur substantial costs and diversion of management and technical personnel, whether or not the litigation is ultimately determined in our favor.



We have been involved in the patent litigations summarized below:



Embrex v. Service Engineering Corporation and Edward G. Bounds, Jr.



In September 1996, we filed a patent infringement suit against Service Engineering Corporation and Edward G. Bounds, Jr. in the U.S. District Court for the Eastern
District of North Carolina. This suit concluded in July 1998 with the jury finding the patent valid and willfully infringed by the defendants and a judgment being entered in September 1998, which included a monetary award of $2,612,885.



In July 2000, the U.S. Court of Appeals for the Federal Circuit affirmed the award to
Embrex of approximately $1.5 million in litigation expenses and costs and upheld the finding of willful infringement. However, the appeals court vacated the award of direct infringement damages and remanded that issue to the district court for
further proceedings. These proceedings were opened in August 2000, but were stayed early in 2001.



Embrex v. Breuil S.A. and New Tech Solutions, Inc.



In December 2003, we filed suit in the U.S. District Court for the Eastern District of North Carolina against Breuil S.A. of Landivisiau, France, and New Tech Solutions, Inc. of Gainesville, GA, asserting patent
infringement. We allege that each of the defendants development of candling and in ovo selective injection devices, designed to compete with our patented Inovoject® system injection with Vaccine Saver® option and Egg
Remover® system, infringes two of our patents related to our proprietary apparatus and methods for distinguishing live eggs from infertile or dead eggs and for selectively injecting specific eggs identified as suitable for
inoculation as well as the apparatus performing this function. We seek injunctive relief and monetary damages and have asked for a jury trial. The defendants have denied infringement and alleged that our two patents are invalid. Because of this
lawsuit, our results of operations have been impacted and will continue to be impacted by the costs of pursuing this litigation. Moreover, there can be no assurance we will prevail in our claims against Breuil S.A. or New Tech Solutions, Inc. Even
if the court finds in our favor, we have no assurances that any damage award will exceed our costs of pursuing this litigation or that we would be able to collect any damages from either defendant.



Embrex v. Avitech, LLC



In August 2004, we filed suit in the U.S. District Court for the Middle District of North Carolina against Avitech, LLC of Hebron, Maryland
asserting patent infringement. We allege that Avitechs injection system, designed to compete with Embrexs patented Inovoject®system, infringes one of the our patents related to our proprietary apparatus and methods for accurately and precisely injecting eggs to the same depth and location when the eggs are of varying sizes
and may be presented to the injection apparatus in somewhat different orientations. We seek injunctive relief and monetary damages and have asked for a jury trial. The defendant has denied that the North Carolina court has jurisdiction and has moved
to



- 30 -



---

##### Table of Contents

dismiss or, in the alternative, for transfer to the United States District Court in Maryland. We opposed the
defendants motion and assert that the North Carolina court has jurisdiction. The court heard oral argument on the motion, and advised that the court will issue an opinion. If the defendants motion is resolved in our favor, the lawsuit
will proceed in the North Carolina court. Because of this lawsuit, our results of operations have been impacted and will continue to be affected by the costs of pursuing this litigation. Moreover, there can be no assurance we will prevail in our
claims against Avitech, LLC. Even if the court finds in our favor, we have no assurances that any damage award will exceed our costs of pursuing this litigation or that we would be able to collect any damages from the defendant.



THE LOSS OF KEY COLLABORATORS, SUPPLIERS AND OTHER KEY PARTIES COULD ADVERSELY AFFECT
OUR FINANCIAL RESULTS



We currently conduct our operations with
various third-party collaborators, suppliers, licensors or licensees. We plan to continue developing these relationships and believe our present and future collaborators, suppliers, licensors and licensees will perform their obligations under their
agreements with us, based on an economic motivation to succeed. However, financial or other difficulties facing these parties may affect the amount and timing of funds and other resources devoted by the parties under these agreements. In addition,
disagreements may arise with these third parties which could delay or lead to the termination of the development or commercialization of new products, or result in litigation or arbitration, which would be time consuming and expensive. Thus, there
is no assurance that we will develop any new products or generate any revenues from these collaborative agreements.



WE ARE SUBJECT TO AN INHERENT RISK OF PRODUCT LIABILITY



The development, manufacture, distribution and marketing of our products involve an inherent risk of product liability claims and associated adverse publicity. These
claims may be made even with respect to those products that are manufactured in licensed and approved facilities or that otherwise possess regulatory approval for commercial sale. These claims could expose us to significant liabilities that could
prevent or interfere with the development and marketing of our products. Product liability claims could require us to spend significant time and money in litigation or pay significant damages. Although we currently maintain liability insurance that
we believe is adequate to cover the Companys potential exposure in this area, there can be no assurance that the coverage limits of our policies will be adequate. Such insurance is expensive, difficult to obtain and may not continue to be
available on acceptable terms or at all.



GOVERNMENT REGULATION AND THE
NEED FOR REGULATORY APPROVAL MAY ADVERSELY AFFECT OUR BUSINESS



Regulatory approval required in various areas of our business may materially adversely affect our operations. The primary emphasis of these requirements is to assure the safety and effectiveness of our products. While the use of the
Inovoject®system is not subject to regulatory approval in the United States, it may
require regulatory approval by foreign agencies. Also, research and development activities and the investigation, manufacture and sale of poultry health products are subject to regulatory approval in the United States by either the USDA or the
United States Food & Drug Administration, or FDA, and state agencies, as well as by foreign agencies. Obtaining regulatory approval is a lengthy, costly and uncertain process. Approval by the USDA generally takes 1 to 3 years, while approval by
the FDA may take 5 or more years. The Company currently has no products under development which would require approval by the FDA. Various problems may arise during the regulatory approval process and may have an adverse impact on our operations.
Changes in the policies of U.S. and foreign regulatory bodies could increase the time required to obtain regulatory approval for each new product. Delays in obtaining approval may materially adversely affect the marketing of, and the ability to
receive revenues and royalties from, products developed by us. There is no assurance that any future products developed by us or by our collaborative partners will receive regulatory approval without lengthy delays, if at all. Even when approved,
regulators may impose limitations on the uses for which the product may be



- 31 -



---

##### Table of Contents

marketed and may continue to review a product after approving it for marketing. Regulators may impose restrictions and
sanctions, including banning the continued sale of the product, if they discover problems with the product or its manufacturer.



Pursuant to some of our licensing or joint development agreements, the licensees or joint developers bear the costs associated with the regulatory approval process for
some products. We plan to continue to enter into these types of agreements in the future. If we cannot generate sufficient funds from operations or enter into licensing or joint development agreements to develop products, we may not have the
financial resources to complete the regulatory approval process with respect to all or any of the products currently under development. We may need to obtain approval from appropriate regulators before we can sell our products in a particular
jurisdiction.



Other regulations apply or may apply to research and
manufacturing activities, including federal, state and local laws, regulations and recommendations relating to the following:



| |  |  | safe working conditions;
| | - |  | ------------------------



| |  |  | laboratory and manufacturing practices; and
| | - |  | -------------------------------------------



| |  |  | use and disposal of hazardous substances used in conjunction with research activities.
| | - |  | --------------------------------------------------------------------------------------



It is difficult to predict the extent to which these or other government regulations may adversely impact the production and marketing of
our products.



OUR INABILITY TO ATTRACT AND RETAIN KEY PERSONNEL COULD
ADVERSELY AFFECT OUR BUSINESS



We must continue to attract and retain
experienced and highly educated scientific and management personnel and advisors to be able to develop marketable products and maintain a competitive research and technological position. Competition for qualified employees among biotechnology
companies is intense. There can be no assurance that we will be able to continue to attract and retain qualified staff. The departure of any key executive or our inability to recruit and retain key scientific or management personnel could have an
adverse affect on our business, results of operations or financial condition. Our ability to replace key individuals may be difficult and may take an extended period of time because of the limited number of individuals in the biotechnology industry
with the breadth of skills and experience required to develop and commercialize products successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate such individuals. We have obtained
insurance in the amount of $1,000,000 on the life of Randall L. Marcuson, our President and Chief Executive Officer, of which we are the sole beneficiary. This amount may not be sufficient to compensate us for the loss of his services.



IF WE CANNOT CONTINUE TO PROVIDE TIMELY SUPPORT AND MAINTENANCE TO OUR CUSTOMERS,
OUR BUSINESS MAY SUFFER



We are required to supply, support, and
maintain large numbers of Inovoject®systems at our customers hatcheries on a timely
basis at a reasonable cost to us. There can be no assurance that we will be able to continue to provide these services on a timely or cost-effective basis. If we are unable to do so, our customers may reduce their use of our products, which could
materially adversely affect our operating results.



WE HAVE ANTI-TAKEOVER
DEFENSES THAT COULD DISCOURAGE OR DELAY A TAKEOVER



Provisions of our
certificate of incorporation and bylaws could have the effect of discouraging or delaying an acquisition of our company. For example, the Board of Directors has the authority to issue up to



- 32 -



---

##### Table of Contents

15,000,000 shares of Preferred Stock in one or more series and to determine the designations, preferences and relative
rights and qualifications, limitations or restrictions of the shares constituting any series of Preferred Stock, without any further vote or action by the shareholders. The issuance of Preferred Stock by the Board of Directors could affect the
rights of the holders of Common Stock. For example, an issuance could result in a class of securities outstanding that would have preferences with respect to voting rights and dividends and in liquidation over the Common Stock, and could (upon
conversion or otherwise) enjoy all of the rights applicable to Common Stock. The authority of the Board of Directors to issue Preferred Stock potentially could be used to discourage attempts by others to obtain control of us through merger, tender
offer, proxy contest or otherwise by making these attempts more difficult to achieve or more costly. The Board of Directors may issue the Preferred Stock without shareholder approval and such Preferred Stock could have voting and conversion rights
that could materially adversely affect the voting power of the holders of Common Stock. No agreements or understandings currently exist for the issuance of Preferred Stock, and the Board of Directors has no present intention to issue any Preferred
Stock. The Board adopted a shareholder rights plan that could have the effect of discouraging a takeover of us. The rights plan, if triggered, would make it more difficult to acquire us by, among other things, allowing existing shareholders to
acquire additional shares at a substantial discount, thus substantially inhibiting the ability of an interested party to obtain control of the Company.



Item 3. Quantitative and Qualitative Disclosures About Market Risk



Market risk is the risk of potential loss arising from adverse changes in market rates and prices. The Companys primary market risk exposure is in changes in foreign currency exchange rates. Approximately 34%,
32% and 31% of Embrexs revenues for the years ended 2004, 2003 and 2002, respectively, were derived from our operations outside the United States. Our consolidated financial statements are denominated in U.S. dollars and, accordingly, changes
in the exchange rates between foreign currencies and the U.S. dollar will affect the translation of our subsidiaries financial results into U.S. dollars for purposes of reporting our consolidated financial results. From 2003 to 2004, the
British pound and euro each strengthened 8% against the U.S. dollar and to a lesser extent select Latin American currencies also strengthened against the U.S. dollar. If average exchange rates during the second-quarter of 2005 had remained the same
as the average exchange rates for these currencies during the same period of 2004, then the Companys 2005 revenues would have been approximately $25.4 million instead of $25.8 million representing a year-to-year growth rate of 8% as compared
to the actual exchange-adjusted growth rate of 9%.



Accumulated currency
translation adjustments recorded as a separate component (addition) of shareholders equity were $0.4 million at June 30, 2005 as compared with $0.2 million at December 31, 2004. This $0.2 million change was mainly attributable to the
depreciating U.S. dollar with respect to currencies in which the Company has an exchange rate risk. Since our Latin American subsidiaries have grown substantially, the exchange rate change between the U.S. dollar and Brazilian Real were the primary
contributors to the $0.2 million change in currency translation adjustments. To date, the Company has not utilized any derivative financial instruments or other hedging instruments to affect this exposure.



In addition to currency translation risk, the Company is subject to transaction risk.
Transaction risk is the risk of potential loss arising from adverse changes in exchange rates from the date invoices are issued until the receipts are collected. Most of Embrexs transaction risk resides in the Companys largest
subsidiary, Embrex Europe, where accrued revenues are recorded in the functional currency, British pounds. However, most of Embrex Europes revenues are invoiced in U.S. dollars or euros. When revenues are collected, there is a risk that
changes in the respective exchange rates could cause the amount collected (when converted to British pounds) to be less than originally accrued. As the Companys business grows in other markets, such as Brazil, we expect that transaction and
translation risk may increase in these markets.



- 33 -



---

##### Table of Contents

As of June 30, 2005, the Companys exposure to market risk for a change in interest rates is related solely to debt
outstanding under the term loan used for construction and equipping of the Inovocox manufacturing facility. At June 30, 2005, the variable-rate debt outstanding that is exposed to fluctuations in the market rate of interest under this term loan totaled $8.8 million. The definitive extent of
the Companys interest rate risk under this term loan is not quantifiable or predictable because of the variability of future interest rates and business financing requirements. Based on the current balance outstanding, an increase in the LIBOR
rate of 100 basis points would increase the Companys annualized interest expense by approximately $0.1 million.



Item 4. Controls and Procedures



Disclosure Controls and Procedures



The Company maintains
disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the the Securities Exchange Act of 1934, as amended (the Exchange Act)) that are designed to provide reasonable assurances that information required to
be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commissions rules and forms, and that
such information is accumulated and communicated to management, including the Companys Chief Executive Officer and Vice President, Finance and Administration (the Companys Chief Financial Officer), as appropriate, to allow timely
decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of
achieving the desired control objectives, as the Companys are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.



An evaluation was carried out under the supervision and with the participation of the
Companys management, including its Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Companys disclosure controls and procedures. Based upon that evaluation, the Chief Executive
Officer and Chief Financial Officer believe, as of the end of the period covered by this report, the Companys disclosure controls and procedures are effective in that they provide reasonable assurances that information required to be disclosed
by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commissions rules and forms. The Chief Executive
Officer and the Chief Financial Officer reached this conclusion with respect to the Companys disclosure controls and procedures notwithstanding the fact that they also concluded, as described below, that the Companys internal control
over financial reporting was not effective as of December 31, 2004, based upon their findings of a material weakness with respect to accounting for income taxes. While the Chief Executive Officer and Chief Financial Officer believe there is overlap
between disclosure controls and procedures and internal control over financial reporting, they have concluded that a material weakness in internal controls limited to accounting for income taxes, as further explained below, does not cause the
Companys disclosure controls and procedures to be ineffective. The Company believes that the inter-relation of disclosure controls and procedures and internal control over financial reporting is not yet well defined by law, regulation or
interpretation. The Company believes that disclosure controls and procedures and internal control over financial reporting are intended to be two distinct standards, otherwise the requirements for separate determinations as to their effectiveness
would be redundant. Nonetheless, if disclosure controls and procedures and internal control over financial reporting are intended to be in effect substantially the same standard under these circumstances, then in such case, the Companys
disclosure controls and procedures also would be ineffective for the same reasons discussed below that the Chief Executive Officer and the Chief Financial Officer have concluded that the Companys internal control over financial reporting was
not effective.



- 34 -



---

##### Table of Contents

Internal Control Over Financial Reporting



The Company made no changes in its internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange
Act) during the fiscal quarter ending June 30, 2005 that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting, other than as described below.



As previously reported in the Companys Annual Report on Form 10-K for the year ended
December 31, 2004, the Companys management assessed the effectiveness of the Companys internal control over financial reporting as of December 31, 2004 and concluded that a combination of control deficiencies relating to inadequate
staffing and a lack of sufficient tax accounting expertise constituted a material weakness in internal controls over the preparation and review of the Companys accounting for income taxes as of December 31, 2004. As a result of this material
weakness, management concluded that, as of December 31, 2004, the Companys internal control over financial reporting was not effective.



The Company has taken certain steps to improve procedures for the preparation and review of the Companys accounting for income taxes, including the engagement of
external tax expertise. To date, the Company has contracted with an independent third-party accounting firm with domestic and international tax expertise, as well as another independent firm to provide tax return preparation services.



During the second quarter of fiscal 2005, the Company implemented changes to its internal
controls designed to improve its internal controls structure in the area of information technology (IT). The changes included further segregation of responsibilities within the IT area, the preparation of additional change control
documentation, and revisions to various policies and procedures relating to the IT area. The Company is evaluating additional steps to take, including the hiring of additional personnel and outside consultants to enhance segregation of
responsibilities.



The Company plans to continue an on-going review and
evaluation of its internal control over financial reporting and may make changes as it deems desirable based on its reviews and evaluations.



All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable
assurance with respect to financial statement preparation and presentation.



PART II - OTHER INFORMATION



Item 1. Legal Proceedings



For a
description of patent infringement proceedings initiated by the Company and related legal proceedings, see the Companys Form 10-K for the year ended December 31, 2004 filed with the Securities and Exchange Commission on March 15, 2005.



Item 2. Unregistered Sales of Equity Securities and Use of Proceeds



|Not | applicable.
|--- | -----------



Item 3. Defaults Upon Senior Securities



Not applicable.



- 35 -



---

##### Table of Contents

Item 4. Submission of Matters to a Vote of Security Holders



On May 19, 2005, the Annual Meeting of Shareholders was held and the following matter was submitted to the shareholders for a vote. There were 7,676,274 shares represented at the meeting in person or by proxy and set
forth below is a brief description of the matter voted on and the number of votes cast for, against or withheld, as well as the number of abstentions and broker non-votes. There were no broker non-votes or abstentions regarding the election of
directors.



Election of Board of Directors:



|                         |  |           |  |                |  |          
|------------------------ |  | --------- |  | -------------- |  | ---------
|Director                 |  | Votes For |  | Votes Withheld |  | Totals   
|C. Daniel Blackshear     |  | 6,575,779 |  | 1,100,495      |  | 7,676,274
|David Castaldi           |  | 6,604,210 |  | 1,072,064      |  | 7,676,274
|Peter J. Holzer          |  | 6,604,601 |  | 1,071,673      |  | 7,676,274
|Ganesh M. Kishore, Ph.D. |  | 6,605,043 |  | 1,071,231      |  | 7,676,274
|John E. Klein            |  | 6,602,510 |  | 1,073,764      |  | 7,676,274
|Randall L. Marcuson      |  | 6,544,073 |  | 1,132,201      |  | 7,676,274



Item 5. Other Information



Not
applicable.



Item 6. Exhibits



|              |  |                                                                                                                                        
|------------- |  | ---------------------------------------------------------------------------------------------------------------------------------------
|ExhibitNumber |  | Description of Document                                                                                                                
|31.1          |  | Certification of Principal Executive Officer of Periodic Report Pursuant to Rule 13a-14(a) or Rule 15d-14(a)                           
|              | 
|31.2          |  | Certification of Principal Financial Officer of Periodic Report Pursuant to Rule 13a-14(a) or Rule 15d-14(a)                           
|              | 
|32.1          |  | Certification of Principal Executive Officer of Periodic Report Pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350
|              | 
|32.2          |  | Certification of Principal Financial Officer of Periodic Report Pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350



- 36 -



---

##### Table of Contents

SIGNATURES



Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



Date: August 2, 2005



EMBREX, INC.By:

/s/ Randall L. MarcusonRandall L. MarcusonPresident and Chief Executive Officer




- 37 -



---

##### Table of Contents

EXHIBIT INDEX



|              |  |                                                                                                                                        
|------------- |  | ---------------------------------------------------------------------------------------------------------------------------------------
|ExhibitNumber |  | Description of Document                                                                                                                
|31.1          |  | Certification of Principal Executive Officer of Periodic Report Pursuant to Rule 13a-14(a) or Rule 15d-14(a)                           
|              | 
|31.2          |  | Certification of Principal Financial Officer of Periodic Report Pursuant to Rule 13a-14(a) or Rule 15d-14(a)                           
|              | 
|32.1          |  | Certification of Principal Executive Officer of Periodic Report Pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350
|              | 
|32.2          |  | Certification of Principal Financial Officer of Periodic Report Pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350



- 38 -